LICENSE & COLLABORATION AGREEMENT



 Exhibit 10.2 
  
 LICENSE AND COLLABORATION AGREEMENT 
  
 BETWEEN 
  
 TOPOTARGET A/S 
  
 AND 
  
 CURAGEN CORPORATION 
  
 DATED AS OF June 3, 2004

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	 









 LICENSE AND COLLABORATION AGREEMENT 
  
 THIS LICENSE AND COLLABORATION AGREEMENT (this “Agreement”), dated as of June 3, 2004, is between TopoTarget A/S,
a company duly organized and existing under the laws of Denmark and having offices at Symbion Science Park, Fruebjergvej 3, 2100 Copenhagen, Denmark (“TOPOTARGET”), and CURAGEN Corporation, a company duly organized and existing under the
laws of the State of Delaware and having offices at 555 Long Wharf Drive, New Haven, CT 06511, USA (“CURAGEN”). 
  
 PRELIMINARY STATEMENTS 
  
 A. TOPOTARGET is a biotechnology company with a development program, a library of compounds, and other intellectual property rights relating to HDAC
Inhibitors. 
  
 B. CURAGEN is a biopharmaceutical company with an
interest in commercializing HDAC Inhibitors in the Territory. 
  
 C. TOPOTARGET and CURAGEN wish to collaborate in connection with the research, development and commercialization of TOPOTARGET HDAC Inhibitors, upon the terms and conditions set forth in this Agreement. 
  
 D. TOPOTARGET and CURAGEN are willing to grant to each other certain rights
owned or controlled by them relating to HDAC Inhibitors in connection with their collaboration, upon the terms and conditions set forth in this Agreement. 
  
 NOW, THEREFORE, in consideration of the foregoing preliminary statements and the mutual covenants and agreements of the Parties contained in this
Agreement, the Parties hereby agree as follows: 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	 










	1.	DEFINITIONS. 

  
 As used in this Agreement, the following terms shall have those meanings set forth in this Section 1 unless the context dictates otherwise. 
  
 1.1 “Affiliate” with respect to either Party, shall
mean any Person controlling, controlled by, or under common control with, such Party. For purposes of this Section 1.1, “control” shall mean (i) the possession, directly or indirectly, of the power to direct the management or policies of a
Person, whether through the ownership of voting securities, by contract or otherwise, or (ii) the beneficial ownership (as such term is defined in the 1934 Act) of at least 50% of the voting securities or other ownership interest of a Person.

  
 1.2 “Back-Up Product” shall mean,
subject to Section 7.2(e), an HDAC Inhibitor other than the First Product or any Future Product that (i) could be claimed under U.S. patent law by the broadest independent composition of matter claim that could be supported by the disclosure of any
single Patent within the TOPOTARGET Licensed Technology that covers such First Product or Future Product and (ii) demonstrates at least equivalent efficacy in the same animal model of any disease that was the determining model for selecting the
First Product or Future Product for development in such disease, adjusted for therapeutic index (defined by the exposure of the First or Future Product at NOAEL (“no observed adverse effect level”) divided by exposure of the First or
Future Product at the ED50 in the same animal species). 
  
 1.3
“Collaboration Product” shall mean the First Product, the Future Products and Back-Up Products, unless and until CURAGEN’s license to any such Collaboration Product under this Agreement has terminated in accordance with the
terms hereof. 
  
 1.4 “Combination
Product” means any Covered Product containing (whether in the same formulation or packaged together) both a pharmaceutically active agent which is itself a Covered Product and one or more other pharmaceutically active agents which are not
Covered Products. 
  
 1.5 “Confidential
Information” shall have the meaning set forth in Section 12.1. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	2









 1.6 “Controlled” shall mean the legal authority or right of a Party hereto or an
Affiliate of a Party to grant a license or sublicense of intellectual property rights to the other Party hereto to effectuate the purposes of this Agreement, or to otherwise disclose proprietary, trade secret information, or other Confidential
Information to such other Party, without breaching the terms of any agreement with a Third Party. 
  
 1.7 “Covered Product” shall mean any Collaboration Product the manufacture, sale or use of which in the Field in the country of
sale is covered by a Valid Claim of any Patent included in the TOPOTARGET Licensed Technology, the TOPOTARGET Collaboration Technology or the Joint Collaboration Technology. 
  
 1.8 “CURAGEN Clinical Data” shall have the meaning set forth in Section 8.5. 
  
 1.9 “CURAGEN Collaboration Technology” shall mean all
Inventions and Know-How first conceived and reduced to practice solely by employees of CURAGEN or of any Third Party working on behalf of or for the benefit of CURAGEN and/or in whose Inventions and Know-How CURAGEN shall have secured rights, in
each case in the course of or in connection with the Research Program, as well as any and all Patents covering same. 
  
 1.10 “CURAGEN Licensed Technology” shall mean all Patents owned or controlled by, or licensed to, CURAGEN, and all Know-How and
Inventions developed, owned or controlled by, or licensed to, CURAGEN, as of the Effective Date, or acquired by or licensed to CURAGEN after the Effective Date to the extent that such Patents, Know-How and/or Inventions are not included within any
CURAGEN Collaboration Technology or Joint Collaboration Technology, and which, in the reasonable opinion of the Parties, is necessary for the development, manufacture, use or sale of the relevant Collaboration Product, or which was actually used in
the Research Program or by CURAGEN in the development, manufacture, use or sale of such Collaboration Product, all to the extent that CURAGEN has the right to license or otherwise make available such Patents, Know-How and Inventions to TOPOTARGET
hereunder. 
  
 1.11 “CURAGEN Trademarks”
shall have the meaning set forth in Section 8.8. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	3









 1.12 “Development Program” shall mean the development efforts to be conducted by
the Parties as provided in Section 8. 
  
 1.13
“Effective Date” shall mean the date first set forth above. 
  
 1.14 “EU” shall mean the European Union. 
  
 1.15 “FDA” shall mean the United States Food and Drug Administration, or any successor thereto. 
  
 1.16 “Field” shall mean the prevention, diagnosis,
control or treatment of any human disease or condition by use of a Collaboration Product, either as a single agent or in combination with any other therapy. 
  
 1.17 “First Commercial Sale” shall mean, with respect to any Covered Product, the first sale for use or consumption by the general
public of such Covered Product in a country in the Territory after all required marketing and pricing approvals have been granted, or otherwise permitted, by the governing health authority of such country. “First Commercial Sale” shall not
include the sale of any Covered Product for use in clinical trials or for compassionate use prior to the approval of an NDA. 
  
 1.18 “First Product” shall mean any formulation of the chemical compound known as PXD101, as further described in
Exhibit A. 
  
 1.19 “Future
Product(s)” shall mean, subject to Sections 7.2(c), (d) and (f), any formulation of an HDAC Inhibitor other than the First Product which is deemed a Future Product as provided in Section 5.2. 
  
 1.20 “HDAC Inhibitor” shall mean
[***********************************]. 
  
 1.21
“IND” shall mean an Investigational New Drug Application to be filed with the FDA, or the equivalent thereof in other countries or regulatory jurisdictions. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	4









 1.22 “Invention” shall mean any new or useful method, process, manufacture,
compound or composition of matter, whether or not patentable or copyrightable, or any improvement thereof. 
  
 1.23 “Joint Collaboration Technology” shall mean all Inventions and Know-How first conceived jointly and/or reduced to practice
jointly by one or more employees of CURAGEN (or of any Third Party working on behalf of or for the benefit of CURAGEN and/or in whose Inventions and Know-How CURAGEN otherwise has rights) and one or more employees of TOPOTARGET (or of any Third
Party working on behalf of or for the benefit of TOPOTARGET and/or in whose Inventions and Know-How TOPOTARGET otherwise has rights), or first conceived by such employees of one Party and reduced to practice by such employees of the other Party, in
all cases during the performance of the Parties’ respective obligations under the Agreement, as well as any and all Patents covering same. It is understood, however, that no compounds in TOPOTARGET’s library of HDAC Inhibitors at the
outset of the Research Program shall be brought within the “Joint Collaboration Technology” by virtue of CURAGEN and TOPOTARGET employees or Third Parties working on their behalf jointly reducing to practice or demonstrating utility of
such compound in any medical or clinical application or indication. 
  
 1.24 “Joint Steering Committee” shall mean the entity organized and acting pursuant to Section 4. 
  
 1.25 “Know-How” shall mean unpatented technical and other information which is not in the public domain including information
comprising or relating to discoveries, inventions, data, designs, formulae, methods, models, assays, research plans, procedures, designs for experiments and tests and results of experimentation and testing (including results of research or
development), processes (including manufacturing processes, specifications and techniques), laboratory records, chemical, pharmacological, toxicological, clinical, analytical and quality control data, trial data, case report forms, data analyses,
reports or summaries, and information contained in submissions to and information from ethical committees and regulatory authorities (provided that inclusion of the latter information as “Know-How” shall not be understood to 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	5









 
limit or restrict a Party’s ability to submit appropriate information to an ethical committee and/or regulatory authority). Know-How includes rights
protecting Know-How. No combination of information shall be deemed to be within the public domain because individual features of the information are in the public domain. No information shall be deemed to be within the public domain because it is
embraced by more general information in the public domain. 
  
 1.26 “NDA” shall mean a New Drug Application to be filed with the FDA, or the equivalent thereof in other countries or regulatory jurisdictions. 
  
 1.27 “Net Sales” shall mean, with respect to any Covered Product, the gross amount invoiced to Third
Parties by CURAGEN, its Affiliates or its Sublicensees, as the case may be, for such Covered Product, commencing with the First Commercial Sale of such Covered Product, less deductions for: (i) trade, quantity and/or cash discounts actually granted
to the extent consistently applied by CURAGEN to its products; (ii) credits, refunds and allowances (including, without limitation, cash, credit and free goods allowances) actually allowed or given for chargebacks but only to the extent it is a
sales related deduction which is accounted for within CURAGEN on a product-by-product basis, (iii) retroactive price reductions, billing errors and rebates (including, without limitation, government-mandated and managed healthcare negotiated
rebates), credits and refunds for Covered Product that is rejected, spoiled, damaged, outdated or returned, to the extent each was actually allowed or given and as consistently applied by CURAGEN to its products; (iv) freight, postage, shipping,
insurance and other transportation costs actually incurred in transporting Covered Product to a Third Party; and (v) taxes, tariffs, customs duties, surcharges and other governmental charges incurred in connection with the sale, exportation or
importation of Covered Product. For reductions identified in items (i) – (iv) that are not accounted for on a product by product basis by CURAGEN, such deductions may not exceed [*********(***)] of the total gross sales price without the prior
approval of TOPOTARGET, such approval to not be unreasonably withheld. The books and records of CURAGEN, its Affiliates or its Sublicensees, as the case may be, shall be maintained in accordance with the generally accepted accounting principles,
consistently applied, and with sufficient particulars as necessary to determine such deductions and amounts. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	6









 In the event that CURAGEN, its Affiliates, or Sublicensees intend to sell a Combination Product, the
Parties shall meet approximately one (1) year prior to the anticipated Launch of such Combination Product to negotiate in good faith and agree to an appropriate adjustment to Net Sales to reflect the relative significance and value of the Covered
Product and the other pharmaceutically active agent(s) contained in the Combination Product on a country-by-country basis. If there is a stand alone Covered Product on the market in a given country which corresponds to the HDAC Inhibitor within the
Combination Product, the adjustment to Net Sales for such country shall equal the Net Sales of the Combination Product multiplied by a fraction, the numerator of which is the current price of the Covered Product and the denominator of which is the
reasonable fair market value, in the aggregate, of all pharmaceutically active agents contained in the Combination Product in each case in the same country as the country in which the Combination Product is to be sold. If no such Covered Product is
on the market in a given country, and if, after good faith negotiations (not to exceed ninety (90) days), the Parties cannot agree to an appropriate adjustment, Net Sales for such country shall equal Net Sales of the Combination Product multiplied
by a fraction, the numerator of which is the reasonable fair market value of the Product and the denominator of which is the reasonable fair market value, in the aggregate, of all pharmaceutically active agents contained in the Combination Product.
If the Parties cannot agree on the “fair market value” of either the Product or any of the pharmaceutically active agents, the Parties shall retain a panel of three valuation experts to make such a determination, the costs for which shall
be shared equally by the Parties. Each Party shall select one expert, who shall not be an employee of either and who shall have at least at least a university degree in economics and five (5) years experience in conducting such valuations. The two
experts shall promptly select a mutually agreeable third expert with like qualifications. The experts shall render a written opinion binding on the Parties for the relevant countries within thirty (30) days, which shall be binding, with no right of
appeal, on both Parties and any Affiliates and Sublicensees. 
  
 Notwithstanding the foregoing, in connection with (X) any sale or other disposition of Covered Product that is not a bona fide, arms length transaction for money, or (Y) any other use of Covered Product that does not result in or give rise
to sales revenue that is customary in the 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	7









 
country in which such use takes place (except as provided in the next paragraph), Net Sales shall be calculated at the relevant open market price in the
country in which such sale, disposition or use takes place, or, if such price is not reasonably ascertainable, at a reasonable price, assessed on an arms length basis, for the goods and/or services received in consideration of the sale, disposition
or use of Covered Product. 
  
 CURAGEN’s or any of its Affiliate’s
transfer of Covered Product to another Affiliate or a Sublicensee shall not result in any Net Sales, unless such Covered Product is consumed by such Affiliate or Sublicensee in the course of its commercial activities. In such case, Net Sales shall
occur upon such other Affiliate’s or Sublicensee’s sale of such Covered Product to a Third Party. Further, the disposition of Covered Product for, or the use of Covered Product in, pre-clinical or clinical (Phase I – III) trials or
other market-focused (Phase IV or V) trials or free samples shall not result in any Net Sales, unless CURAGEN, its Affiliate or Sublicensee is permitted to receive payment for Covered Product used in clinical trials which includes a reasonable
profit. 
  
 1.28 “NIH” shall mean the U.S.
National Institutes of Health. 
  
 1.29 “1934
Act” shall mean the Securities Exchange Act of 1934, as amended, and all regulations promulgated pursuant thereto from time to time. 
  
 1.30 “Party” shall mean TOPOTARGET or CURAGEN and, when used in the plural, shall mean TOPOTARGET and CURAGEN. 
  
 1.31 “Patents” shall mean all letters patent and
patent applications, as well as any and all substitutions, extensions, supplementary protection certificates, renewals, continuations, continuations-in-part, divisions, patents-of-addition and/or reissues thereof. 
  
 1.32 “Person” shall mean any natural person,
corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government or any agency or political subdivision thereof. 
  
 1.33 “Phase II” shall mean within oncology, one or
more trials with enough patients (usually 20 patients or more) in at least one treatment arm designed to determine a reasonable 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	8









 
estimate of response rate (usually a confidence interval narrow enough to be acceptable as evidence of activity versus active or historical control data).
For other indications, one or more randomized controlled trials of sufficient size to determine with 80% power an a priori agreed upon clinical effect. 
  
 1.34 “Phase III” shall mean one or more pivotal trials designed and powered for registration with FDA. Agreement from the FDA on
study design must be obtained before Phase III initiation in a pre-Phase III meeting or through FDA’s Special Protocol Assessment Procedures. 
  
 1.35 “Phase II Initiation” shall mean the day when the first patient in the first Phase II clinical trial of the relevant
Collaboration Product, which trial has been approved by the Joint Steering Committee, gets dosed. If the trial is a Phase I/II trial, the Initiation of Phase II refers to the day when the first patient in the treatment arm designed to determine a
reasonable estimate of response rate gets dosed. 
  
 1.36
“Phase III Initiation” shall mean the day when the first patient in the first Phase III clinical trial of the relevant Collaboration Product, which trial has been approved by the Joint Steering Committee, gets dosed. 

 
 1.37 “Research Plan” shall have the meaning set
forth in Section 5.1. 
  
 1.38 “Research
Program” shall mean the research program that is conducted by TOPOTARGET and CURAGEN pursuant to Section 5. 
  
 1.39 “Research Term” shall have the meaning set forth in Section 5.8. 
  
 1.40 “Royalty Term” shall mean, with respect to each
Covered Product sold in a country, the period of time commencing on the First Commercial Sale in such country and ending on the date of expiration of the last Valid Claim of any Patent included in the TOPOTARGET Licensed Technology, or the
TOPOTARGET Collaboration Technology, or the Joint Collaboration Technology in such country which is directed to the composition of matter or use in the Field of such Covered Product or a pharmaceutical preparation containing such 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	9









 
Covered Product, or which is directed to a manufacturing process actually used for the manufacture of such Covered Product; provided, however, that in
any country where only Valid Claims of such manufacturing process patents remain, the Royalty Term shall end on the last day of the first calendar quarter in which units of generic versions of the Covered Product sold in such country equal or exceed
[******(****)] of all units of Covered Product sold in such country. 
  
 1.41 “Sublicensee” shall mean a Third Party to which CURAGEN has granted sublicense rights under the TOPOTARGET Licensed Technology, TOPOTARGET Collaboration Technology, and/or Joint Collaboration Technology.

  
 1.42 “Substances” shall have the
meaning assigned thereto in Section 5.6. 
  
 1.43
“Supply Agreement” shall have the meaning assigned thereto in Section 11.2. 
  
 1.44 “Territory” shall mean all of the countries in the entire world other than those countries in the TOPOTARGET Territory.

  
 1.45 “Third Party” shall mean
any Person who or which is neither a Party nor an Affiliate of a Party. 
  
 1.46 “TOPOTARGET Clinical Studies” shall have the meaning assigned thereto in Section 8.4. 
  
 1.47 “TOPOTARGET Collaboration Technology” shall mean all Inventions and Know-How first conceived and reduced to practice solely
by employees of TOPOTARGET, or of any Third Party working on behalf of or for the benefit of TOPOTARGET and/or in whose Inventions and Know-How TOPOTARGET shall have secured rights, in each case in the course of or in connection with the Research
Program, as well as any and all Patents covering same. It is understood, however, that no compounds in TOPOTARGET’s library of HDAC Inhibitors at the outset of the Research Program shall be brought within the “TOPOTARGET Collaboration
Technology” (as opposed to being within “TOPOTARGET Licensed Technology”) by virtue of TOPOTARGET reducing to practice or demonstrating utility of such compound in any medical 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	10









 
or clinical application or indication during the course of or in connection with the Research Program. 
  
 1.48 “TOPOTARGET Licensed Technology” shall mean all
Patents owned or controlled by, or licensed to, TOPOTARGET, and all Know-How and Inventions developed, owned or controlled by, or licensed to, TOPOTARGET, as of the Effective Date, or which are developed, acquired by or licensed to TOPOTARGET after
the Effective Date to the extent such Patents, Know-How and/or Inventions are not included within any TOPOTARGET Collaboration Technology or Joint Collaboration Technology, and which, in the reasonable opinion of the Parties, is necessary for or may
be useful in the development, manufacture, use or sale of Collaboration Products in the Field in the Territory, all to the extent that TOPOTARGET has the right to license or otherwise make available such Patents, Know-How and Inventions to CURAGEN
hereunder. A list of all such Patents in existence on the Effective Date is included in Exhibit A attached. 
  
 1.49 “TOPOTARGET Territory” shall mean the following countries: Norway, Iceland, Switzerland, Austria, Belgium, Denmark, Finland,
France, Germany, Greece, Ireland, Italy, Luxembourg, The Netherlands, Portugal, Spain, Sweden, United Kingdom, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovakia, Slovenia, Russian Federation, Ukraine, Albania,
Andorra, Belarus, Bosnia-Hercegovina, Bulgaria, Croatia, Liechtenstein, Moldova, Monaco, Romania, Serbia-Montenegro, Yugoslavia (Macedonia), Turkey, and Israel. 
  

1.50 “Valid Claim” shall mean a claim of any issued letters patent that, in each case, has not been held invalid or
unenforceable by final decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that is not admitted to be invalid or unenforceable through reissue, disclaimer or
otherwise. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	11










	2.	REPRESENTATIONS AND WARRANTIES. 

  
 2.1 Representations and Warranties of Both Parties. Each Party represents and warrants to the other Party that, as of the Effective Date:

  
 (a) Such Party is duly organized and validly
existing under the laws of the jurisdiction of its incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof; 
  
 (b) Such Party has taken all corporate action necessary to authorize the execution and delivery of this
Agreement and the performance of its obligations under this Agreement; 
  
 (c) This Agreement is a legal and valid obligation of such Party, binding upon such Party and enforceable against such Party in accordance with the terms of this Agreement, except as such enforceability may be
affected by laws affecting creditors’ rights generally. The execution, delivery and performance of this Agreement by such Party do not and shall not conflict with any agreement, instrument or understanding, oral or written, to which such Party
is a party or by which such Party may be bound, except as expressly set forth in Section 2.2(g), and do not and shall not, to the best of such Party’s knowledge, violate any law or regulation of any court, governmental body or administrative or
other agency having authority over such Party. All consents, approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by such Party in connection with the execution, delivery and performance of
this Agreement have been obtained; 
  
 (d) Such
Party has sufficient facilities, experienced personnel and other capabilities to enable it to perform its obligations under this Agreement; and 
  
 (e) No Person has or will have, as a result of the transactions contemplated by this Agreement, any right, interest or valid claim against
or upon such Party for any commission, fee or other compensation as a finder or broker because of any act by such Party or of any agent of such Party. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	12









 2.2 Additional Representations and Warranties of TOPOTARGET. TOPOTARGET represents and
warrants to CURAGEN that, as of the Effective Date: 
  
 (a) TOPOTARGET and/or its Affiliates are the owner of, or have exclusive rights to, all of the Patents included in the TOPOTARGET Licensed Technology in existence on the Effective Date, and have the exclusive right to grant the licenses
granted under this Agreement; 
  
 (b) All such
Patents consist of either patent applications that have been filed and are pending and actively being prosecuted as of the Effective Date, or issued letters patent that are in full force and effect and have been maintained through the Effective
Date; 
  
 (c) TOPOTARGET is not aware of any
asserted or unasserted claim or demand which it believes can be enforced by a Third Party against any such Patents; 
  
 (d) To the best of TOPOTARGET’s knowledge and belief, the practice of all inventions claimed in such Patents and the performance of
the Research Program as currently contemplated by the Parties does not and shall not infringe upon or conflict with any patent, copyright or other proprietary right of any Third Party; 
  
 (e) TOPOTARGET and/or its Affiliates are the owner(s) of, or have exclusive rights to all of the Know-How
and Inventions included in the TOPOTARGET Licensed Technology in existence on the Effective Date, and have the right to grant the licenses granted under this Agreement; 
  
 (f) To the best of TOPOTARGET’s knowledge and belief, such Know-How and Inventions were not obtained by
TOPOTARGET in violation of any contractual or fiduciary obligation to which TOPOTARGET, or any of its employees or staff members are or were bound, or by the misappropriation of the trade secrets of any Third Party; 
  
 (g) TOPOTARGET has not entered into any agreement with any
Third Party, except for The NATIONAL INSTITUTES OF HEALTH/NATIONAL CANCER INSTITUTE, LEO PHARMA A/S and the WORLD HEALTH ORGANIZATION, as set out in Section 3 below, which is in conflict with the rights granted to CURAGEN under to this Agreement,
and the execution and performance of this Agreement by TOPOTARGET do not and shall not violate any agreement or undertaking to which TOPOTARGET is a party; and 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	13









 (h) To the best of TOPOTARGET’s knowledge and belief, all of the data and
information that TOPOTARGET has provided to CURAGEN prior to the Effective Date relating to such Patents, Know-How and Inventions, are reasonably accurate, and to the best of TOPOTARGET’s knowledge and belief, TOPOTARGET has not omitted
therefrom any material data or information in TOPOTARGET’s possession or control reasonably in advance of the Effective Date concerning same that a reasonable Person in CURAGEN’s position would want to have examined prior to executing this
Agreement. 
  
 2.3 Disclaimer. THE FOREGOING
REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY SET FORTH HEREIN. TOPOTARGET AND CURAGEN DISCLAIM ALL OTHER REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO EACH OF
THEIR RESEARCH, DEVELOPMENT AND COMMERCIALIZATION EFFORTS HEREUNDER, INCLUDING, WITHOUT LIMITATION, WHETHER THE PRODUCTS CAN BE SUCCESSFULLY DEVELOPED OR MARKETED, THE ACCURACY, PERFORMANCE, UTILITY, RELIABILITY, TECHNOLOGICAL OR COMMERCIAL VALUE,
COMPREHENSIVENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE WHATSOEVER OF THE PRODUCTS. 
  

	3.	THIRD PARTY AGREEMENTS, EXCLUSIVITY. 

  
 3.1 Representations and Warranties of TOPOTARGET with respect to Collaborative Research and Development Agreement
(“CRADA”). TOPOTARGET represents and warrants to CURAGEN that, as of the Effective Date. 
  
 (a) TOPOTARGET has entered into a Letter of Intent for Proposed Collaborative Research and Development Agreement with the NIH dated as of
March 24, 2004 (the “CRADA LOI”), a copy of which has been furnished to CURAGEN; 
  
 (b) TOPOTARGET and NIH are diligently pursuing execution of a formal Collaborative Research and Development Agreement (“CRADA”),
but have not yet entered such 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	14









 
an agreement. TOPOTARGET shall include CURAGEN as a party to the CRADA, or else TOPOTARGET shall not include any aspect of clinical research in the CRADA and
shall use its best efforts to cause any aspects of the proposed CRADA which are relevant to clinical research to be embodied in a separate CRADA between CURAGEN and NIH; and 
  
 (c) TOPOTARGET shall include in the CRADA provision(s) permitting CURAGEN to receive all information
described under Section 3.2, and permitting CURAGEN employees to participate on the CRADA Steering Committee as described under Section 3.2 and CURAGEN shall do the same for TOPOTARGET if CURAGEN enters into any CRADA as provided above. 

 
 3.2 TOPOTARGET Obligations. TOPOTARGET agrees that during
the term of the CRADA: 
  
 (a) TOPOTARGET will
designate two CURAGEN employees, as selected by CURAGEN from time to time, as representatives on the CRADA Steering Committee (as defined in the CRADA), provided that all matters relating to the CRADA shall be discussed by the Joint Steering
Committee or its designated subcommittees, as applicable, pursuant to Article 4 below, and provided further that all official communications and/or decisions on behalf of CURAGEN and/or TOPOTARGET with respect to any CRADA shall be communicated to
the CRADA Steering Committee and/or NIH by the TOPOTARGET representatives of the CRADA Steering Committee with respect to any pre-clinical products and by the CURAGEN representatives of the CRADA Steering Committee with respect to any products in
clinical trials. 
  
 (b) TOPOTARGET will use
commercially reasonable efforts to fulfill all of its material obligations under the CRADA, to the extent such obligations have not been expressly delegated to CURAGEN hereunder; 
  
 (c) TOPOTARGET shall not enter into any subsequent agreement with the NIH that modifies or amends the CRADA
in any way that could potentially adversely affect CURAGEN’s rights under this Agreement without CURAGEN’s prior written consent, which shall not be unreasonably withheld, and shall provide CURAGEN with a copy of all 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	15









 
modifications to or amendments of the CRADA, regardless of whether CURAGEN’s consent was required with respect thereto; 
  
 (d) TOPOTARGET shall not terminate the CRADA in whole or in
part, directly or indirectly, without CURAGEN’s prior written consent, which shall not be unreasonably withheld; provided, however, that the Joint Steering Committee shall have the right, upon written notice to TOPOTARGET, to require
TOPOTARGET to terminate the CRADA, in whole or in part, in accordance with its terms at any time, if in the reasonable judgment of the Joint Steering Committee the continuation of the CRADA will adversely impact the clinical development of
Collaboration Products in the Territory; 
  
 (e)
TOPOTARGET shall request the NIH to allow TOPOTARGET and CURAGEN to be involved in the planning of any Data Safety Monitoring Board (DSMB) and to be involved in any Serious Adverse Events (SAE) communication cascades; 
  
 (f) TOPOTARGET shall promptly notify CURAGEN and furnish
CURAGEN with copies of all reports and other communications TOPOTARGET receives from NIH pursuant to the CRADA that relate to the subject matter of this Agreement, including those related to DSMB or SAE; 
  
 (g) TOPOTARGET shall allow CURAGEN to review and approve
prior to submission to NIH all reports and other communications that TOPOTARGET intends to furnish to NIH which relate to the subject matter of this Agreement; 
  

(h) TOPOTARGET shall furnish CURAGEN with copies of all notices received by TOPOTARGET relating to any alleged breach or default of any
material obligation by TOPOTARGET under the CRADA within three business days after TOPOTARGET’s receipt thereof and, if TOPOTARGET cannot or chooses not to cure or otherwise resolve any such alleged breach or default, TOPOTARGET shall allow
CURAGEN, in CURAGEN’s sole discretion, to cure or otherwise resolve any such alleged breach or default; and 
  
 (i) Except for the initiation of litigation of any type against NIH or the National Cancer Institute, TOPOTARGET shall use all
commercially reasonable efforts, at 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	16









 
TOPOTARGET’s sole expense, to exercise and enjoy the direct benefit of all of TOPOTARGET’s affirmative rights under the CRADA, to the extent they
relate to Collaboration Products in the Field and in the Territory, including without limitation obtaining exclusive license rights in the Field and Territory to all Subject Inventions as defined therein. 
  
 (j) In the event that CURAGEN enters into any CRADA as
provided in Section 3.1(b), CURAGEN shall adhere to each of (b) through (i) above, with the designations of the Parties reversed. 
  
 3.3 Rights of, and Obligations to LEO PHARMA A/S and the World Health Organization. 
  
 (a) Leo. 
  
 (i) The Parties acknowledge that TOPOTARGET has entered into
a Material Transfer and Screening Agreement with LEO PHARMA A/S (“Leo”) dated as of October 27, 2003 (the “Leo Agreement”), and that pursuant to such Leo Agreement, Leo may obtain worldwide rights to certain HDAC Inhibitors for
use solely in the field of dermatological diseases, as defined in the Leo Agreement (the “Leo Field”). The Parties further acknowledge that TOPOTARGET is prohibited from entering into any agreement regarding the screening or development in
the Leo Field of the 10 HDAC Inhibitors provided to Leo for evaluation pursuant to the Leo Agreement during the term of the Leo Agreement, as defined therein. The Parties hereby agree that notwithstanding anything herein to the contrary, the rights
granted to CURAGEN by TOPOTARGET hereunder, including without limitation any grant of “exclusive” rights, shall be subject to TOPOTARGET’s obligations to Leo, and the rights granted to Leo, under the Leo Agreement; provided,
however, that CURAGEN shall have the right to approve in advance the terms and conditions of any license to be granted to Leo regarding the use of HDAC Inhibitors in the Leo Field (such approval to not be unreasonably withheld), and that
TOPOTARGET shall pay to CURAGEN [******(*****)] of any consideration received by TOPOTARGET under any such license, net of 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	17









 
TOPOTARGET’s fully-burdened labor costs for any collaborative research or development activities required to be performed by TOPOTARGET pursuant to any
such license and its out-of-pocket expenses related to the granting of such license, which payments shall be made within thirty (30) days of receipt of any such consideration. 
  
 (ii) TOPOTARGET hereby represents and warrants to CURAGEN than it has disclosed to CURAGEN the identity of
the 10 HDAC Inhibitors that it has provided to Leo pursuant to the Leo Agreement and that it will inform CURAGEN of the status of any and all license negotiations which are conducted with Leo pursuant to the Leo Agreement. 
  
 (b) The World Health Organization. 
  
 (i) The Parties acknowledge that TOPOTARGET has transferred
HDAC Inhibitors to the World Health Organization (“WHO”) pursuant to a letter dated as of March 28, 2003 (the “WHO Agreement”), and that pursuant to such WHO Agreement, WHO may desire to obtain rights to certain HDAC Inhibitors
for use in the field of malarial diseases (the “WHO Field”). The Parties hereby agree that notwithstanding anything herein to the contrary, the rights granted to CURAGEN by TOPOTARGET hereunder, including without limitation any grant of
“exclusive” rights, shall be subject to any of TOPOTARGET’s obligations to WHO, and any rights granted to WHO, under the WHO Agreement; provided, however, that CURAGEN shall have the right to approve in advance the terms and
conditions of any license to be granted to WHO regarding the use of HDAC Inhibitors in the WHO Field (such approval to not be unreasonably withheld), and that TOPOTARGET shall pay to CURAGEN [******(*****)] of any consideration received by
TOPOTARGET under any such license, received by TOPOTARGET under any such license, net of TOPOTARGET’s fully-burdened labor costs for any collaborative research or development activities required to be performed by TOPOTARGET pursuant to any
such license and its out-of-pocket 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	18









 
expenses related to the granting of such license, which payments shall be made within thirty (30) days of receipt of any such consideration. 
  
 3.4 Exclusivity. (a) During the Research Term - For the
duration of the Research Term, CURAGEN shall be TOPOTARGET’s exclusive collaborator for HDAC Inhibitors in the Territory, and CURAGEN therefore agrees that, during the Research Term, CURAGEN and its Affiliates shall not, for the benefit of
CURAGEN or any Third Party, acquire rights from any Third Party, perform any research or clinical development for, collaborate with or grant licenses to any Third Party, in all cases with respect to any HDAC Inhibitors other than Collaboration
Products, except as provided in Section 3.4(d) below. 
  
 (b) Without limiting the generality of Section 3.4(a), during the Research Term, (i) TOPOTARGET agrees that it shall not, itself or through another party, perform research for, collaborate with or grant licenses to any Third Party with
respect to any HDAC Inhibitor for use in the Field within the Territory, and will not, itself or through another party, undertake such activities with respect to any HDAC Inhibitor for use in the Field within the Territory for the benefit of any
Third Party, except in connection with the Third Party Agreements described in Section 3.1 hereof or as otherwise expressly permitted herein in Section 3.3, and (ii) TOPOTARGET shall be permitted, itself and/or with one or more other parties, to
perform research for, collaborate with and/or grant licenses to any Third Party with respect to any HDAC Inhibitor for development, sale and/or use solely within the TOPOTARGET Territory, subject only to the provisions of Section 3.5 hereof and to
the provisions of Section 8.4 hereof. 
  
 (c)
Following the Research Term. TOPOTARGET agrees that, following the Research Term, it shall not, itself or through another party, for the benefit of TOPOTARGET or any Third Party, perform research for, collaborate with or grant licenses to any Third
Party with respect to any Collaboration Product for use in the Territory, or perform clinical development anywhere in the world with respect to, or market or sell any HDAC Inhibitor in a therapeutic indication (e.g., lung cancer) within the
Territory, for which, at the time of the commencement of any such research, collaboration, license grant, clinical development, marketing or selling, any 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	19









 
Collaboration Product is being marketed or developed, or is planned for development based on demonstrated efficacy in a relevant animal model of a disease
(“CURAGEN Indications”) for use in the Territory in the Field and such Collaboration Product continues to be diligently developed in that indication by CURAGEN. CURAGEN shall regularly advise TOPOTARGET of such development and planning for
development, and TOPOTARGET shall notify CURAGEN of any intent to exercise its rights hereunder within the Territory and provide CURAGEN with [******(*****)] business days in which to update any such information as to which indications are currently
in development or planned for development based on demonstrated efficacy in a relevant animal model of a disease. In the event that any such prohibited clinical development of a TOPOTARGET HDAC Inhibitor is conducted by an independent Third Party
which leads to the use of any such HDAC Inhibitor in a CURAGEN Indication in competition with actual sales of a Collaboration Product that has been developed specifically for that indication, the Parties shall agree in good faith on appropriate
compensation to CURAGEN [***************************************************************]; PROVIDED THAT such compensation shall not exceed the lesser of (i) [****************** *********************************] or (ii)
[***********************************]. In the event that the parties cannot agree on appropriate compensation after ninety (90) days of good faith negotiations, the parties shall refer the matter to an independent expert agreed upon by the parties,
who will set such compensation at an amount not to exceed the lesser of (i) and (ii) above. The decision of the expert shall be binding on the parties, and any compensation provided to CURAGEN pursuant to this Section 3.4(c) shall be CURAGEN’s
exclusive remedy and TOPOTARGET’s sole obligation and liability with respect to any independent Third Party clinical development as described herein. 
  
 (d) The Parties hereby agree that, during the Research Term, CURAGEN shall not be permitted to license an HDAC Inhibitor or acquire a
Third Party with an HDAC Inhibitor program and CURAGEN shall prohibit its Affiliates from licensing HDAC Inhibitors from Third Parties or acquiring a Third Party with an HDAC Inhibitor program as provided above. Notwithstanding the foregoing, in the
event that CURAGEN is acquired by a Third Party which has an HDAC Inhibitor program, such transaction shall not be precluded by this Section 3.4 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	20









 
and, subject to compliance with Sections 7.2(f), 8.2(a) and Article 12, CURAGEN shall be free to develop and commercialize any HDAC Inhibitors arising from
such Third Party’s program alone or in conjunction with such Third Party following any such transaction. 
  
 (e) TOPOTARGET’s activities with respect to HDAC Inhibitors which are not Collaboration Products shall not be limited except as
expressly provided in this section. Nothing in this Section 3.4 shall in any way be deemed to affect the scope of any licenses or rights expressly granted to CURAGEN pursuant to Section 7 below, or the Parties’ obligations pursuant to Section 8
or Section 12 below. 
  
 3.5 Licensing by TOPOTARGET
within the TOPOTARGET Territory; CURAGEN’s Right of First Negotiation. 
  
 (a) In the event that TOPOTARGET wishes to grant any Third Party licenses or rights in any country within the TOPOTARGET Territory with
respect to the development, marketing or distribution of a Collaboration Product (regardless of whether TOPOTARGET or such Third Party initiated discussions of such sublicensing), it may do so during the Research Term only after such Collaboration
Product has completed Phase II clinical studies and after the Research Term it may do so at any development stage. In any event, before making or accepting any such Third Party offer, as the case may be, TOPOTARGET shall first propose to grant such
rights to CURAGEN. Such proposal shall be in writing, be made in good faith, and set forth terms no less favorable to CURAGEN than those to be offered to, or offered by, such Third Party. Within [********] days after receipt of any such proposal,
CURAGEN shall notify TOPOTARGET as to whether CURAGEN wishes to enter into negotiations for such rights. If CURAGEN provides timely notice that it wishes to do so, then the Parties shall conduct exclusive negotiations and use good faith efforts to
conclude an agreement within [********] days thereafter. If the Parties are unable to agree upon the terms of such agreement despite the use of good faith efforts for a period of at least [********] days, CURAGEN shall put its proposal in writing
(the “Last Offer”). Thereafter, TOPOTARGET shall be free to grant a license or other rights to Third Parties to the rights described in such Last Offer, but only during a [*****(***)] month period following receipt of such Last Offer and
only on terms more 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	21









 
favorable to TOPOTARGET as the Last Offer made by CURAGEN. If, on the other hand, (i) CURAGEN gives TOPOTARGET notice that CURAGEN does not wish to enter
into any such license, or (ii) CURAGEN does not respond to TOPOTARGET’s initial proposal within [********] days after receipt thereof, then TOPOTARGET shall be free to grant a license or other rights as outlined in the initial proposal to Third
Parties on any terms, but only during a [*****(***)] month period following such initial proposal. 
  
 (b) For [*****(***)] months after the Effective Date, TOPOTARGET shall exclusively negotiate in good faith with CURAGEN for a license to
its E2F program. At CURAGEN’s option, such license can include screening assays and/or compounds. 
  

	4.	JOINT STEERING COMMITTEE 

  
 4.1 Members. The Parties shall establish a Joint Steering Committee (the “Joint Steering Committee”), which shall comprise three
representatives designated by each Party (or such other number as the Parties may agree). The initial members of the Joint Steering Committee are set forth on Exhibit B. Members of the Joint Steering Committee may be represented at any
meeting by a designee who is appointed by such member for such meeting and who has authority to act on behalf of such member. The chairperson shall be selected by CURAGEN and the initial chairperson is designated on Exhibit B. Each Party
shall be free to replace its representative members with new appointees who have authority to act on behalf of such Party, on notice to the other Party. 
  
 4.2 Responsibilities. The Joint Steering Committee shall be responsible for overseeing and directing the Research Program and the
Development Program. Its duties, therein, shall include, without limitation: 
  
 (i) evaluating and determining scientific criteria to be implemented under the Research Program; 
  
 (ii) after providing thirty (30) days notice, proposing, approving and, from time to time, updating and modifying the Research Plans and
Development Program plans; 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	22









 (iii) providing guidance for the implementation of the Research Plans and Development
Program plans; 
  
 (iv) determining the
deliverables each Party is responsible for under the Research Plans and Development Program; 
  
 (v) reviewing expenditures made by TOPOTARGET to verify that such expenditures conformed with the budget established in the annual
Research Plan 
  
 (vi) allocating
responsibilities and resources between the Parties with respect to the Research Program and Development Program; 
  
 (vii) determining whether to commence or terminate various projects under the Research Program; 
  
 (viii) setting patent filing policies and making patent
filing determinations, as contemplated by Sections 6.4(a) – (d); 
  
 (ix) evaluating data from the Research Program and designating Future Products for further development; 
  
 (x) reviewing the results of any clinical trials conducted by CURAGEN or by TOPOTARGET pursuant to the Development Program and assigning
to the Parties’ activities under the Development Program based on such results, as appropriate; 
  
 (xi) reviewing and evaluating progress, milestone achievement and diligence under the Research Program and the Development Program,
provided that the Joint Steering Committee shall not have authority to make any determination that either Party is in breach of its obligations under this Agreement or any Research Plan or other plan created by the Joint Steering Committee;

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	23









 (xii) providing for the exchange of information between the Parties relating to the
Research Program and the Development Program; 
  
 (xiii) addressing issues and resolving differences that may arise between the Parties with respect to the Research Program and the Development Program; 
  
 (xiv) approving all CRADA research plans and amendments thereto and all other official decisions to be
communicated to NIH with respect to any CRADA; and 
  
 (xv) approving any Party’s entrance into agreements and other arrangements with third party service providers for services necessary to effectuate the purposes of the Research Plan. 
  
 4.3 Research Team and Development Team. The Joint Steering
Committee shall, at request of either Party, be authorized to constitute separate committees to oversee the Research Program and/or the Development Program, which committees will operate under written guidelines set forth by the Joint Steering
Committee and which are consistent with the terms of this Agreement. Such committees shall have the same allocation of members from each party as the allocation for the Joint Steering Committee. 
  
 4.4 Meetings. The Joint Steering Committee shall meet at least
once every calendar quarter, and more frequently as the Parties deem appropriate, on such dates and at such times as the Parties shall agree, on 10 days’ written notice to the other Party unless such notice is waived by the Parties. The Joint
Steering Committee may convene or be polled or consulted from time to time by means of telecommunications, video conferences or correspondence, as deemed necessary or appropriate by the Parties. To the extent that meetings are held in person, they
shall alternate between the offices of the Parties unless the Parties otherwise agree. The chairperson shall be responsible for sending notices of meetings to all members. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	24









 4.5 Decisions. 
  
 (a) A quorum for a meeting of the Joint Steering Committee shall require the presence of at least one
TOPOTARGET member (or designee) and at least one CURAGEN member (or designee) in person or by telephone. All decisions made or actions taken by the Joint Steering Committee shall be made unanimously by its members, with the TOPOTARGET members
cumulatively having one vote and the CURAGEN members cumulatively having one vote. 
  
 (b) In the event that unanimity cannot be reached by the Joint Steering Committee with respect to a matter that is a subject of its
decision-making authority, (i) any matter concerning the development and commercialization of any First Product or Future Product after the acceptance for filing of an IND by the FDA, or the appropriate scope of any regulatory toxicity studies of
any Future Product, shall be decided by the designated officer of CURAGEN in good faith, taking into account the reasonable commercial interests of TOPOTARGET and the express provisions of this Agreement, and (ii) any matter concerning the
development of any First Product or Future Product prior to the acceptance for filing of an IND by the FDA, or the allocation of any funds provided by CURAGEN pursuant to Section 5.3(a), shall be decided by the designated officer of TOPOTARGET in
good faith, taking into account the reasonable commercial interests of CURAGEN and the express provisions of this Agreement. 
  
 4.6 Minutes. Within 15 days after each Joint Steering Committee meeting, the Chairman, of the Joint Steering Committee or another member of
the Steering Committee designated by the Chairman, shall have prepared and distributed minutes of the meeting, which shall provide a description in reasonable detail of the discussions had at the meeting and a list of any actions, decisions or
determinations approved by the Joint Steering Committee. Draft minutes shall circulated to all members of the Joint Steering Committee sufficiently in advance of the next meeting to allow adequate review and comment prior to the meeting. Minutes
shall be approved or disapproved, and revised as necessary, at the next meeting. Final minutes shall be distributed to the members of the Joint Steering Committee. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	25









 4.7 Term. The Joint Steering Committee shall exist until the termination or expiration of
the Research Program and the Development Program. 
  
 4.8
Expenses. Each Party shall be responsible for all travel and related costs for its representatives to attend meetings of, and otherwise participate on, the Joint Steering Committee. 
  

	5.	COLLABORATIVE RESEARCH PROGRAM. 

  
 5.1 Scope of Research Program. The Parties agree to undertake a Research Program for the pre-clinical development of the First Product,
including use as a combination therapy, and for pre-clinical development of Future Products. The Joint Steering Committee shall prepare, or have prepared, and provide to each Party a detailed description, mutually acceptable to the Parties in form
and substance, of the activities to be undertaken during each 12-month period during the Research Program, which shall include a reasonably detailed description of the goals and scope of such research, a corresponding detailed budget for each Party,
the allocation of responsibilities to the respective Parties and a work plan, milestones and project target dates for such period (including the personnel, equipment and facilities that TOPOTARGET or CURAGEN is required to provide) (each such
12-month plan, as may be updated or modified from time to time, a “Research Plan”). The objective of the Research Plan will be to allow and support US IND submissions and submissions to governmental authorities of other countries as
determined by the Joint Steering Committee concerning the First Product and Future Products. The initial Research Plan is attached as Exhibit C. Each subsequent Research Plan shall be embodied in a letter agreement to be executed by the
Parties and shall be finalized at least thirty (30) days prior to the end of the prior twelve-month period. The Joint Steering Committee shall regularly review, update and, as necessary, modify each Research Plan from time to time. The Joint
Steering Committee shall promptly provide each Party with any such updates or modifications. 
  
 5.2 Selection of Future Products. As of the Effective Date, TOPOTARGET shall have disclosed to CURAGEN all HDAC Inhibitors that have met the conditions set forth in Exhibit D and, during the
Research Term, TOPOTARGET shall promptly disclose to CURAGEN all future HDAC Inhibitors Controlled by TOPOTARGET that meet such 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	26









 
conditions, whether identified during the course of performance of the Research Program or otherwise. All such HDAC Inhibitors that meet the conditions set
forth in Exhibit D and that are shown to have efficacy in an animal model other than the [********] model prior to or during the course of the Research Program shall be deemed Future Products for purposes of this Agreement. Each disclosure
hereunder regarding an HDAC Inhibitor shall include the composition of the HDAC Inhibitor and all data with respect thereto in the possession or Control of TOPOTARGET. 
  
 5.3 Support of Research Program. 
  
 (a) Subject to Section 5.3(e), on or before the first day of each calendar quarter during the Research Term,
CURAGEN shall advance one fourth of the annual Research Program budget for TOPOTARGET as specified in the relevant Research Plan via wire transfer into an account designated by TOPOTARGET. Payments for any partial calendar quarter during the
Research Term shall be prorated. Such payments shall cover all pre-clinical development costs incurred by TOPOTARGET in conducting the Research Plan for selected HDAC Inhibitors Controlled by TOPOTARGET and meeting the criteria in Exhibit D,
including animal models of efficacy and ADME, PK, toxicology and mutagenicity studies, and including any such work related to use in combination therapy, and also including all pre-clinical studies (other than regulatory toxicity studies) for Future
Products, and including all relevant product supply costs, in each case as authorized in advance by the Joint Steering Committee under each Research Plan. If any such costs include labor costs for TOPOTARGET employees, they shall be budgeted at an
annual FTE rate of [*********************(********)] which amount includes an allocation of direct overhead expenses, which rate shall be revised annually at TOPOTARGET’s request subject to approval of the Joint Steering Committee. At the end
of each calendar quarter, TOPOTARGET shall provide the STEERING COMMITTEE with a list itemizing expenditures and charges over the preceding quarter. 
  
 (b) At the end of each calendar year, TOPOTARGET shall provide a full accounting to CURAGEN of actual expenditures for work actually done
by TOPOTARGET under the Research Plan during the preceding calendar year. If the expenses and charges of 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	27









 
TOPOTARGET exceed the budgeted amount for any quarter, as such budget may be amended in accordance with the terms hereof, CURAGEN shall have no obligation to
reimburse TOPOTARGET for any such overrun. At the time of the final annual report, any such excess funds shall be carried forward to the next calendar year for use by TOPOTARGET in discharging its duties under the next annual Research Plan. However,
in no case shall any quarterly payment by CURAGEN be reduced or withheld by CURAGEN because of any excess funds remaining in the designated account of TOPOTARGET. 
  
 (c) Costs for regulatory toxicology studies required to support the initial US IND for the First Product
shall be paid from and charged against the Research Program budget as specified in Section 5.3(e). Any costs for any regulatory toxicology studies for any Future Product and for new formulations or different administration schedules of the First
Product shall not be paid from or be charged against the quarterly advances made by CURAGEN pursuant to Section 5.3(a), and shall be CURAGEN’s responsibility unless CURAGEN has provided written notice within thirty (30) days of receipt of
written notice of a Joint Steering Committee recommendation regarding such studies that it does not wish to fund such studies, in which event Section 7.2(d) shall apply. 
  
 (d) In no event shall costs incurred by CURAGEN in carrying out any work directed by the Joint Steering
Committee under Section 5.3(f) be paid for from the funds described in Section 5.3(a) above. Such funds shall also not be used to fund any SAR chemistry or manufacturing process development work performed by TOPOTARGET or any in-vitro research as
described in Section II of Exhibit C hereto performed by either Party, which work shall be funded by the Party who is to perform such work. 
  
 (e) Pursuant to Section 5.3(a), CURAGEN shall be obligated to pay a maximum of US$6,000,000 towards costs of the Research Program over the
first three (3) years of the Research Program and aggregate payments shall not at any time exceed more than $500,000 per quarterly period for all quarterly periods which have elapsed since the Effective Date without CURAGEN’s prior written
consent. The Joint Steering Committee may recommend an increase or an acceleration in such budget to the extent necessary to complete any 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	28









 
relevant work allocated to TOPOTARGET under this Agreement or under the Research Plan; provided, however, that CURAGEN shall not be required to fund
any such excess amount or agree to any acceleration of payments without its prior written consent. In the event that TOPOTARGET’s budgeted expenses as approved by the Joint Steering Committee reach US$6,000,000 prior to the end of the Research
Term, the Research Program shall terminate unless otherwise agreed by the Parties. Neither party shall be liable to the other party for any costs, damages, expenses or other liabilities as a result of such termination, and neither party shall have
any obligation to continue work under the Research Plan following the date of such termination. 
  
 (f) If requested by the Joint Steering Committee, CURAGEN shall utilize its systems biology technologies to support the Research Program,
subject to CURAGEN’s prior approvals, not to be unreasonably withheld, with advance notice to TOPOTARGET. The Joint Steering Committee may decide that CURAGEN should participate in certain activities other than as described above relating to
identification and in-vitro evaluation of Future Products. If so agreed, then such activities shall be documented in writing and reported to TOPOTARGET and the Joint Steering Committee. 
  
 5.4 Conduct of Research Program. During the term of the Research Program, each Party shall: 
  
 (a) undertake an interactive, cooperative Research Program
with the other Party as set forth in the Research Plans, and such other activities that the Joint Steering Committee decides, from time to time, are necessary for the scientific or commercial success of the Research Program, consistent with Article
4, this Agreement, and the intent of the Parties as evidenced by this Agreement; 
  
 (b) use all reasonable efforts and proceed diligently to perform the work set out for such Party to perform under the Research Plan,
including, without limitation, by using personnel with sufficient skills and experience, together with sufficient equipment and facilities; 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	29









 (c) conduct the Research Program in good scientific manner, in compliance with all
requirements of all applicable laws, rules and regulations and all other requirements of any applicable good laboratory practices and using resources consistent with those that such party would dedicate to its own research efforts, to attempt to
achieve the objectives of the Research Program in a reasonably efficient and expeditious manner; 
  
 (d) provide the other Party with notice of all significant developments and of all milestones achieved in the performance of the Research
Program as they occur, in accordance with any guidelines established by the Joint Steering Committee; 
  
 (e) promptly provide an invention disclosure report to the other Party with respect to any Invention included in the TOPOTARGET Licensed
Technology, TOPOTARGET Collaboration Technology, CURAGEN Collaboration Technology or Joint Collaboration Technology; 
  
 (f) allow representatives of the other Party, upon reasonable notice and during normal business hours, and subject to reasonable
restrictions necessary to protect the confidentiality of such Party’s other programs, to visit the facilities of such Party where the Research Program is being conducted, and consult informally, during such visits and by telephone, with such
Party’s personnel performing work on the Research Program; and 
  
 (g) with respect to each Party, ensure that all of its employees and agents involved in the Research Program on such Party’s behalf agree, in writing, to assign to such Party, directly or indirectly, such
Person’s entire interest in and to any and all Inventions arising from such involvement. 
  
 5.5 Records. 
  
 (a) TOPOTARGET and CURAGEN each shall maintain records in a manner suitable for carrying out the purposes of the Research Program, and in sufficient detail and in good scientific manner (which shall be complete and accurate in all material
respects) and in a form required under all applicable laws and regulations. Each Party shall use reasonable efforts to maintain its records, and to require its subcontractors to do so, in an electronic form suitable 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	30









 
for electronic filing with any regulatory authority. In addition, TOPOTARGET shall retain records of personnel commitments and other expenditures made in
support of the Research Program in sufficient detail to satisfy its reporting requirements to the Steering Committee. CURAGEN shall maintain its records in a similar form. 
  
 (b) TOPOTARGET and CURAGEN shall share all information contained in such records, and each shall have the
right, during normal business hours, upon reasonable notice and subject to such reasonable procedures as the other Party may require, to inspect and copy all such records of the other Party relating specifically to the Research Program to the extent
reasonably required for the performance of the inspecting Party’s obligations, or exercise of such Party’s rights, under this Agreement. TOPOTARGET and CURAGEN each shall maintain such records and the information of the other Party
contained therein in confidence in accordance with Section 12 and shall not use such records or information except to the extent otherwise permitted by this Agreement. 
  
 5.6 Material Transfer. In order to facilitate the Research Program, either Party may provide to the other
Party certain biological materials or chemical compounds (collectively, the “Substances”) owned by or licensed to the supplying Party (other than under this Agreement) for use by the other Party in furtherance of the Research Program.
Except as otherwise provided under this Agreement, all Substances delivered to the other Party shall remain the sole property of the supplying Party, shall be used only in furtherance of the Research Program or the receiving Party’s rights
under this Agreement, shall remain under the sole control of the other Party. Substances shall not be used by or delivered to any Third Party except under a written Material Transfer Agreement containing terms and conditions substantially similar to
those contained in the form attached as Exhibit E. Any rights to inventions acquired by either Party pursuant to any such Material Transfer Agreement shall be deemed Joint Collaboration Technology. The Substances supplied under this Section
5.6 shall not be used in research or testing involving human subjects, and must be used otherwise with prudence and appropriate caution in any experimental work, since not all of their characteristics may be known. THE SUBSTANCES ARE PROVIDED
HEREUNDER “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	31









 
LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE SUBSTANCES WILL NOT INFRINGE
OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. 
  
 5.7 Liability. Each Party shall be responsible for, and hereby assumes, any and all risks of personal injury or property damage attributable to the grossly negligent or willful acts or omissions, during the term of the
Research Program, of such Party, its Affiliates, Sublicensees and their respective directors, officers, employees and agents. 
  
 5.8 Term of Research Program. The term of the Research Program (“Research Term”) shall commence on the Effective Date, and shall
continue until the third anniversary of the Effective Date, unless earlier terminated as provided herein; provided, however, that CURAGEN may elect, at its sole discretion, to extend the Research Term for one or more additional 12-month
periods by committing to fund any such continued Research Program at a level of at least US$2,000,000 per year, such amount, to the extent greater than $2,000,000, to be negotiated in good faith, giving due consideration to prior research costs and
expenses under the Research Program and mutually agreed to by the Parties on or before the expiration of the prior period. Notice of any such election shall be made, if at all, at least 90 days prior to the relevant anniversary of the Effective
Date. In the event that the election is made but the parties cannot agree upon appropriate consideration by the expiration of the prior period, then the Research Program shall terminate as of such date. 
  
 5.9 Termination of Research Program; Effect. 
  
 (a) At any time during the term of the Research Program,
either Party shall have the right to terminate the Research Program upon 30 days’ written notice to the other Party, in the event that: 
  
 (i) the other Party is acquired (whether through merger, consolidation, acquisition (directly or indirectly) of stock representing 50% or
more of the outstanding voting stock or other of its equity securities, sale of all or 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	32









 
substantially all of its assets, or otherwise) by a Third Party which is reasonably perceived by the non-acquired Party as a competitor with respect to HDAC
Inhibitors or not capable of meeting the requirements of the Research Program or the purposes of this Agreement; or 
  
 (ii) Either Party has become entitled to terminate this Agreement under clause (b) or (c) of Section 15.3. 
  
 (iii) Notwithstanding any other provisions of this
Agreement, CURAGEN shall have the right to terminate the Research Program at any time after the first anniversary of the Effective Date upon three (3) months’ notice to TOPOTARGET (x) in its entirety or solely with respect to additional Future
Products, and with no penalty, in the event that CURAGEN reasonably concludes, in good faith and based on the results of the Research Program and other appropriate scientific and commercial information available to CURAGEN, which conclusion and the
grounds therefor shall be presented to the Joint Steering Committee in writing, that it is not likely that any additional Future Products will be identified for which an IND can properly be filed in the United States or that any Future Product which
is likely to be identified for which an IND can properly be filed in the United States is not likely to be sufficiently commercially successful to warrant the cost of filing an IND and conducting the necessary clinical trial to obtain approval of an
NDA in the United States; or (y) for any reason upon payment of a penalty equal to 50% of any remaining unexpended portion of the US $6,000,000 in research funding to be provided pursuant to Section 5.3. In the event the Research Program is
terminated under Section 5.9(a)(iii)(x) only with respect to additional Future Products, the Parties will negotiate, in good faith, a revised budget for the continued development of then existing Collaboration Products. If the parties cannot agree
upon appropriate budget within thirty (30) days, then this matter will be referred to the Chief Executive Officers of the Parties for resolution through good faith negotiations. If the budget is not agreed by such individuals within thirty (30)
days, then the 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	33









 
Parties shall utilize a mutually agreed upon expert, who shall decide on the appropriate reductions from the current budget, if any, and whose decision will
be binding on the parties. 
  
 Either Party shall promptly notify the other Party
of the occurrence of any of the events specified in Sections 5.9(a)(i) or (ii). 
  
 (b) At any time during the term of the Research Program, either Party (the “terminating Party”) shall have the right to
terminate the Research Program upon notice to the other Party (the “defaulting Party”) in the event the defaulting Party materially defaults with respect to any of its material obligations in connection with the Research Program and fails
to cure such default within 60 days after the receipt of a notice from the terminating Party specifying the nature of, and requiring the remedy of, such default. 
  
 (c) In the event of termination of the Research Program by CURAGEN pursuant to Section 5.9(a) or (b), or by
TOPOTARGET pursuant to Section 5.9(a)(i), CURAGEN may elect to have the Agreement and the license rights granted hereunder continue in effect as follows: CURAGEN shall thereafter be permitted to continue development and commercialization within the
Territory with respect to the First Product and all Future Products identified pursuant to Section 5.2 prior to such termination, provided that such activities are not contrary to the terms of this Agreement and that the provisions of this Agreement
are observed at all times, including, but not limited to, Section 7.2(f), Article 8 and others requiring diligence in development and commercialization, payment of fees and milestones under this Article and Article 9, and termination under Article
15. TOPOTARGET shall (i) promptly transfer to CURAGEN copies, whether in written or electronic form, of all data, reports, and records, in TOPOTARGET’s possession or control, relating to TOPOTARGET Licensed Technology and/or TOPOTARGET
Collaboration Technology but only to the extent required to enable CURAGEN to continue to conduct the Research Program with respect to the Future Products identified under Section 5.2, and all to the extent not previously disclosed to CURAGEN; (ii)
return to CURAGEN all relevant records and materials, whether in written or electronic form, in TOPOTARGET’s possession or control containing Confidential Information of CURAGEN and 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	34









 
(iii) furnish to CURAGEN all unused Substances provided to TOPOTARGET by CURAGEN in connection with the Research Program. Thereafter, CURAGEN shall have no
further obligation to fund the Research Program and, except as provided in Article 11, TOPOTARGET shall not thereafter be obligated to provide CURAGEN with any Collaboration Product(s) in inventory or be obligated to continue to supply any such
product for purposes of the Research Program. 
  
 (d) In the event of termination of the Research Program by TOPOTARGET pursuant to Section 5.9 (a)(ii) or (b), or a termination by CURAGEN pursuant to Section 5.9(a)(i) or (iii), TOPOTARGET may elect to have the Agreement and the license
rights granted hereunder continue in effect as follows: TOPOTARGET shall thereafter be permitted to continue development and commercialization within the TOPOTARGET Territory with respect to the First Product and all Future Products, provided that
such activities are not contrary to the terms of this Agreement. CURAGEN shall (i) promptly provide TOPOTARGET with copies, whether in written or electronic form, of all data, reports, and records, in CURAGEN’s possession or control, relating
to any CURAGEN Licensed Technology, CURAGEN Collaboration Technology, or CURAGEN’s interest in Joint Collaboration Technology but only to the extent required to enable TOPOTARGET to continue to conduct of the Research Program, all to the extent
not previously disclosed to TOPOTARGET; (ii) return to TOPOTARGET all relevant records and materials, whether in written or electronic form, in CURAGEN’s possession or control containing Confidential Information of TOPOTARGET; and (iii) furnish
to TOPOTARGET all unused Substances provided to CURAGEN by TOPOTARGET in connection with the Research Program, and TOPOTARGET may elect to have the licenses granted to it pursuant to this Agreement and the rights granted to it pursuant to this
Agreement continue in effect, subject to the provisions of this Agreement relating to such activities. 
  
 (e) Either Party’s termination of the Research Program pursuant to this Section 5.9 shall be without prejudice to, and shall not
affect, any of the Parties’ respective rights and obligations under this Agreement that do not specifically relate to the Research Program. Without limiting the generality of the foregoing, in the event of a termination by either CURAGEN or
TOPOTARGET of the Research Program pursuant to Section 5.9(a) or (b), either terminating Party’s right to exploit the licenses granted to it hereunder, in accordance with the 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	35









 
terms of this Agreement, shall not be terminated but shall continue in effect as further provided in Section 5.9(c) and 5.9(d) as relevant. 
  

	6.	OWNERSHIP; PATENT PROTECTION. 

  
 6.1 Ownership of CURAGEN Collaboration Technology. Except as otherwise provided in this Agreement, the entire right, title and interest in
and to all CURAGEN Collaboration Technology shall be owned solely by CURAGEN. 
  
 6.2 Ownership of TOPOTARGET Licensed Technology, TOPOTARGET Collaboration Technology. Except as otherwise provided in this Agreement, the entire right, title and interest in and to all TOPOTARGET
Licensed Technology and TOPOTARGET Collaboration Technology shall be owned solely by TOPOTARGET. 
  
 6.3 Ownership of Joint Collaboration Technology. Except as otherwise provided in this Agreement, the right, title and interest in and to all
Joint Collaboration Technology shall be owned jointly and in undivided shares by TOPOTARGET and CURAGEN. 
  
 6.4 Patent Filing, Prosecution and Maintenance. 
  
 (a) Reasonably promptly after the Effective Date the Joint Steering Committee, in consultation with the Parties’ respective patent
counsel, shall agree upon a patent filing policy with respect to Collaboration Products. In addition, from time to time, the Joint Steering Committee shall determine, in accordance with such policy, whether and in what jurisdictions patent
applications should be filed with respect to any Know-How or Inventions included in the TOPOTARGET Licensed Technology, TOPOTARGET Collaboration Technology, CURAGEN Collaboration Technology, and Joint Collaboration Technology. 
  
 (b) Following a determination by the Joint Steering
Committee that a patent application should be filed with respect to any Know-How or Inventions included in the TOPOTARGET Licensed Technology or TOPOTARGET Collaboration Technology, TOPOTARGET, through outside patent counsel (including, without
limitation, foreign patent counsel and agents) reasonably acceptable to CURAGEN and TOPOTARGET, shall promptly 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	36









 
file a patent application with respect thereto in the jurisdiction(s) selected by the Joint Steering Committee, and thereafter TOPOTARGET shall prosecute
such application and maintain any letters patent issuing therefrom. TOPOTARGET shall take all such actions in consultation with CURAGEN and its patent counsel and shall keep CURAGEN apprised as to the status of all pending patent applications. The
costs of filing, prosecuting and maintaining any Patents under this Section 6.4(b) in the Territory shall be borne solely by TOPOTARGET. To the extent that TOPOTARGET disagrees with any such filing, prosecution or maintenance of a Patent under this
Section 6.4(b) and such actions are required by the Joint Steering Committee, the associated costs and fees shall be borne solely by CURAGEN and such Patents shall be assigned to CURAGEN and shall no longer be deemed TOPOTARGET Licensed Technology
or TOPOTARGET Collaboration Technology, as relevant, provided that, solely with respect to Patents on TOPOTARGET Collaboration Technology, such Patents shall be included within the CURAGEN Collaboration Technology for the purpose of the license
granted to TOPOTARGET pursuant to Section 7.4. 
  
 (c) Following a determination by the Joint Steering Committee that a patent application should be filed with respect to any Know-How or Inventions included in any CURAGEN Collaboration Technology, CURAGEN shall promptly file a patent
application with respect thereto in the jurisdiction(s) selected by the Joint Steering Committee, and thereafter CURAGEN shall prosecute such application and maintain any letters patent issuing therefrom. CURAGEN shall take all such actions in
consultation with TOPOTARGET and its patent counsel and shall keep TOPOTARGET apprised as to the status of all pending patent applications. The costs of filing, prosecuting and maintaining any Patents under this Section 6.4(c) shall be borne solely
by CURAGEN. 
  
 (d) Following a determination by
the Joint Steering Committee that a patent application should be filed with respect to a any Know-How or Invention included in the Joint Collaboration Technology, CURAGEN shall promptly file a patent application with respect thereto, in the
Parties’ joint names, in the jurisdiction(s) selected by the Joint Steering Committee, and thereafter CURAGEN shall prosecute such application and maintain any letters patent issuing therefrom. CURAGEN shall take all such actions in
consultation with 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	37









 
TOPOTARGET and shall keep TOPOTARGET apprised as to the status of all pending patent applications. The costs of filing, prosecuting and maintaining any
Patents under this Section 6.4(d) shall be shared equally by the Parties. 
  
 6.5 Termination of Support. Either Party shall have the right to terminate all of its obligations, if any, under Section 6.4 with respect to the filing, prosecution or maintenance of any Patent, from
time to time, upon notice to the other Party; provided, however, that no such notice shall be effective with respect to any such Patent if it is given fewer than 60 days prior to a deadline for taking any action that must be taken in order to
preserve the owner’s rights in such Patent. Upon the delivery of any such effective notice, unless otherwise provided above, such Patent shall be removed from operation of this Agreement, assigned to the non-notifying Party upon request and all
of the notifying Party’s rights, licenses and obligations under this Agreement, if any, with respect to such Patent shall terminate, except those patent expense obligations that shall have accrued prior to the Effective Date of such notice.

  

	7.	GRANT OF LICENSES; RESERVATION OF RIGHTS. 

  
 7.1 Mutual Research Licenses. 
  
 (a) TOPOTARGET hereby grants CURAGEN, during the term of the Research Program, a co-exclusive (solely with TOPOTARGET), paid-up right and
license in the Field throughout the Territory under the TOPOTARGET Licensed Technology, TOPOTARGET Collaboration Technology, and TOPOTARGET’s interest in the Joint Collaboration Technology to conduct the Research Program and to make and use
Collaboration Products in connection with the Research Program, each in accordance with the terms of this Agreement. Notwithstanding the foregoing, the parties recognize that the CRADA described in Section 3.1, and any other agreements entered into
pursuant to Section 3.3, whether executed either before or after the Effective Date, shall not be considered in violation of CURAGEN’s co-exclusivity pursuant to this provision 7.1(a). 
  
 (b) CURAGEN hereby grants TOPOTARGET, during the term of the
Research Program, a co-exclusive (solely with CURAGEN), paid-upright and license in the Field 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	38









 
throughout the TOPOTARGET Territory under the CURAGEN Licensed Technology, the CURAGEN Collaboration Technology and CURAGEN’s interest in the Joint
Collaboration Technology to conduct the Research Program and to make and use Collaboration Products in connection with the Research Program, each in accordance with the terms of this Agreement. 
  
 7.2 CURAGEN Commercialization License. 
  
 (a) Subject to Section 7.2(c), 7.2(d) and 7.2(e), TOPOTARGET
hereby grants to CURAGEN an exclusive (even as to TOPOTARGET), royalty-bearing right and license in the Field throughout the Territory, with the right to grant sublicenses in accordance with the terms of this Agreement, under the TOPOTARGET Licensed
Technology, the TOPOTARGET Collaboration Technology and TOPOTARGET’s interest in the Joint Collaboration Technology to develop, have developed, make, have made, use, sell, offer for sale, and have sold, and to import, have imported, export and
have exported within the Territory, Collaboration Products and, subject to Section 7.2(b), any HDAC Inhibitor that is not a Collaboration Product. 
  
 (b) From and after the date of expiration or termination of the Research Term, any HDAC Inhibitor which is not a Collaboration Product at
such time, shall no longer be subject to the license granted to CURAGEN under Section 7.2(a). 
  
 (c) Notwithstanding Section 7.2(a), for any distinct Future Product for which an IND is filed in any country, whether during or after the
Research Term, if CURAGEN fails to make any payment specified in Section 9.4 for such Future Product within the time period provided therein, such Future Product and its Back-Up Products shall no longer be deemed Collaboration Products and shall be
removed from operation of this Agreement. 
  
 (d)
In addition, for any distinct Future Product for which CURAGEN declines to fund regulatory toxicity studies recommended by the Joint Steering Committee within thirty (30) days of any written notice thereof provided to CURAGEN, such Future Product
and its Back-Up Products shall no longer be deemed Collaboration Products and shall be removed from operation of this Agreement. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	39









 (e) Unless CURAGEN has designated a specific Back-Up Product as a potential replacement
for a Collaboration Product within [*****(****)] years after the first filing of an IND in the Territory for such Collaboration Product, CURAGEN’s license under Section 7.2(a) to Back-Up Products for such Collaboration Product, shall terminate
as of such date and such Back-Up Products shall thereafter no longer be deemed Collaboration Products. If CURAGEN has designated a Back-Up Product prior to such date, such Back-Up Product shall continue to be licensed hereunder, but rights to all
non-designated Back-Up Products shall terminate at such time. 
  
 (f) In order to maintain the license rights of Section 7.2(a), CURAGEN must diligently develop and commercialize Collaboration Products. CURAGEN will have satisfied the foregoing obligation by adhering to the clinical
plan for Collaboration Products as determined by the Joint Steering Committee and, meeting targets for (i) initiating clinical trials: IND within [***(****)******] following completion of regulatory toxicity studies of each Collaboration Product
recommended by the Joint Steering Committee, Phase II within [***(****)******] of Phase I completion, Phase III within [***(****)******] of Phase II completion, and filing at least one (1) NDA within [***(****)******] of Phase III completion
(including all necessary data analysis) and (ii) prosecuting clinical trials: spending a minimum of [******************] for clinical development (all clinical expenses including patient fees, central lab fees and CRO fees, but excluding CURAGEN
internal infrastructure costs) of a Collaboration Product that is in Phase I, [******************] for clinical development of a Collaboration Product that is in Phase II and [******************] for clinical development of a Collaboration Product
that is in Phase III. The failure to achieve any specific target will not mean that CURAGEN has failed to meet the foregoing obligation; provided that CURAGEN can demonstrate that it has used commercially reasonable efforts to do so. Demonstration
of commercial due diligence may include, but is not limited to developing a marketing plan to market the Covered Products in the Territory reflecting activities and resources customary in the industry for similar products, submitting the marketing
plan to TOPOTARGET at least six (6) months prior to launch of the first Covered Product for comment and providing annual updates thereafter, establishing (directly or indirectly) a suitable sales force and committing sufficient 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	40









 
marketing resources and budget to meet the objectives of the marketing plan, and meeting minimum sales targets beginning in the third calendar year after
market launch in the United States. 
  
 7.3 Sublicensing by
CURAGEN. 
  
 (a) CURAGEN shall have the right
to grant sublicenses to any of its Affiliates and/or to Third Parties of the licenses or rights granted to CURAGEN hereunder for purposes of permitting such Affiliate(s) or Third Party to perform CURAGEN’s rights and obligations hereunder,
provided that: (i) CURAGEN shall provide TOPOTARGET written notice within 30 days of identifying said Affiliate or Third Party; (ii) the rights to be granted to any Third Party shall not include rights to any Future Product with respect to which the
take up fee specified in Section 9.4 has not been paid; (iii) CURAGEN shall guarantee and be responsible for ensuring the diligent discharge of CURAGEN’s obligations under, and compliance with all applicable terms of, this Agreement, whether by
CURAGEN or any Sublicensee; (iv) each Affiliate or Sublicensee agrees in writing to keep books and records and permit TOPOTARGET to review such books and records pursuant to the relevant provisions of, and to observe and to be bound by all other
applicable terms of, this Agreement (including, without limitation, those set forth in Sections 8.2, 8.7, 12, 13, 15 and 17); and (v) the rights of TOPOTARGET under this Agreement are preserved in connection with any such sublicensing. CURAGEN shall
promptly provide TOPOTARGET with notice of any sublicense granted pursuant to this Section 7.3. Notwithstanding the foregoing, for any sublicense with respect to a Collaboration Product which has not yet entered Phase II clinical studies, TOPOTARGET
shall have the right within 20 days of any notice provided pursuant to (i) above, to prevent CURAGEN from granting such sublicense if TOPOTARGET notifies CURAGEN that it believes that such proposed Sublicensee lacks sufficient capability to conduct
clinical development of such Collaboration Product, and such belief is reasonable. 
  
 (b) CURAGEN hereby unconditionally guarantees the performance of any of its Affiliates and its Sublicensees hereunder. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	41









 (c) Activities of any Sublicensee shall be subject to milestone, royalty or other
payments as if the activity was conducted by CURAGEN, and CURAGEN shall make payments to TOPOTARGET on behalf of its Sublicensee, unless CURAGEN and TOPOTARGET mutually agree to allow the Sublicensee to make payments directly to TOPOTARGET.

  
 7.4 TOPOTARGET Commercialization License.
CURAGEN hereby grants to TOPOTARGET an exclusive (even as to CURAGEN), royalty-bearing right and license in the Field throughout the TOPOTARGET Territory, with the right to grant sublicenses in accordance with the terms of this Agreement, under the
CURAGEN Licensed Technology, the CURAGEN Collaboration Technology and CURAGEN’s interest in the Joint Collaboration Technology to develop, have developed, make, have made, use, sell, offer for sale, and have sold, and to import, have imported,
export and have exported within the TOPOTARGET Territory, Collaboration Products. 
  
 7.5 Trademark License. CURAGEN hereby grants to TOPOTARGET a fully paid, exclusive right and license, with the right to sublicense subject to CURAGEN’s prior written approval, which approval shall
not be unreasonably withheld, to use the CURAGEN Trademarks in the TOPOTARGET Territory solely in connection with the sale or distribution of Collaboration Products substantially identical to those for which such CURAGEN Trademarks are used by
CURAGEN in the Territory and for which TOPOTARGET has become obligated to pay royalties to CURAGEN pursuant to Section 9.9. TOPOTARGET agrees that prior to any such use, it will submit to CURAGEN for reasonable review samples of the labels and other
materials which depict such CURAGEN Trademarks and which TOPOTARGET intends to use. TOPOTARGET further agrees to cooperate with CURAGEN in connection with CURAGEN’s reasonable efforts to exercise quality control with respect to
TOPOTARGET’s use of any CURAGEN Trademark. To the extent TOPOTARGET desires CURAGEN to enforce against a Third Party the rights to any CURAGEN Trademark in the TOPOTARGET Territory, TOPOTARGET shall be responsible for all costs and expenses
associated therewith. TOPOTARGET agrees that all use of any CURAGEN Trademark by TOPOTARGET shall inure to the benefit of CURAGEN and that TOPOTARGET will not undertake any effort or cause a Third Party to undertake any efforts to challenge the
rights of CURAGEN to any CURAGEN 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	42









 
Trademark. TOPOTARGET hereby unconditionally guarantees the performance of any of its Affiliates or sublicensees with respect to any rights granted
hereunder. 
  

	8.	DEVELOPMENT AND COMMERCIALIZATION. 

  
 8.1 Development Program. The Parties agree to conduct a Development Program as further provided in this Section 8 to coordinate the global
clinical development of the Collaboration Products. The Joint Steering Committee will approve specific Development Program plans for Collaboration Products in accordance with the principles outlined in Exhibit F. All risk-benefit decisions
related to the development of Collaboration Products, including which pre-clinical toxicology studies and safety testing are to be performed, will be made by the Joint Steering Committee. 
  
 8.2 Development And Commercialization Efforts by CURAGEN. 
  
 (a) CURAGEN shall use commercially reasonable efforts,
consistent at least with those described in Section 7.2(f), (including, but not limited to, conducting clinical trials (other than the TOPOTARGET Clinical Studies), filing for regulatory approvals, diligently pursuing such approvals and, upon the
grant of regulatory approval, marketing Collaboration Products) to develop, commercialize and market at least one Collaboration Product in the Field in the Territory. In connection therewith, CURAGEN shall dedicate resources to the development,
commercialization and marketing of Collaboration Products in the Territory that are consistent with the resources that CURAGEN, at all relevant times, would dedicate to products containing compounds with similar commercial potential generated from
CURAGEN’s own research efforts that CURAGEN decided to develop commercially and market. Except as otherwise provided in this Agreement, CURAGEN shall be solely responsible for conducting all such development, commercialization and marketing
activities in the Territory, and for all costs and expenses thereof. 
  
 (b) CURAGEN shall provide TOPOTARGET and the Joint Steering Committee on a timely basis (that is, promptly after generation) with all data, results, reports and other information generated in connection with
CURAGEN’s development, either alone or in 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	43









 
permitted collaboration with any Third Party(ies), of any Collaboration Products in the Territory. CURAGEN shall promptly inform the Joint Steering Committee
regarding all significant developments and issues in connection with any such development of Collaboration Products in the Territory that may arise from time to time. 
  
 8.3 Exchange of Regulatory Information; Ownership of Regulatory Filings. The Parties acknowledge and agree
that as of the Effective Date TOPOTARGET is conducting a Phase I clinical trial of the First Product in the TOPOTARGET Territory. Promptly after the Effective Date, TOPOTARGET shall provide to CURAGEN copies of all data, information and regulatory
filings made or exchanged with any regulatory authority with respect to any Collaboration Product. All INDs, NDAs and other regulatory filings in the TOPOTARGET Territory with respect to any Collaboration Products shall be in the name of, and be
owned solely by, TOPOTARGET. Subject to applicable laws and regulations, unless this Agreement is terminated in its entirety by TOPOTARGET pursuant to Section 15.3 as a result of a payment breach, TOPOTARGET shall provide CURAGEN with the right to
cross-reference any relevant existing regulatory filings and dossiers in connection with CURAGEN’s exercise of the rights granted hereunder. All INDs, NDAs and other regulatory filings in the Territory with respect to any Collaboration Products
shall be in the name of, and be owned solely by, CURAGEN. CURAGEN shall provide to TOPOTARGET copies of all data, information and regulatory filings made or exchanged with any regulatory authority in such countries with respect to any Collaboration
Product, promptly after generation of such data, information or regulatory filing. Subject to applicable laws and regulations, unless this Agreement is terminated by CURAGEN in its entirety pursuant to Section 15.3 as a result of a payment breach,
CURAGEN shall provide TOPOTARGET with the right to cross-reference any such relevant existing regulatory filings and dossiers in connection with TOPOTARGET regulatory activities in the TOPOTARGET Territory. 
  
 8.4 TOPOTARGET’s Development of Collaboration Products

  
 (a) TOPOTARGET shall conduct, at
CURAGEN’s expense, those clinical studies for the First Product and the Future Products in the TOPOTARGET Territory as listed on 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	44









 
Exhibit G attached hereto and as otherwise approved by the Joint Steering Committee (“TOPOTARGET Clinical Studies”). Notwithstanding the
foregoing, CURAGEN shall not be required to pay for the expenses of any TOPOTARGET personnel involved in planning, coordinating or monitoring any such TOPOTARGET Clinical Studies. 
  
 (b) TOPOTARGET shall retain the option to conduct, or have conducted, at its own expense, any clinical trial
it deems appropriate to support registrations for commercialization of Collaboration Products in the TOPOTARGET Territory; provided, however, that all protocols for such trials shall be reviewed with the Joint Steering Committee prior to
initiation of any such trial. 
  
 (c) TOPOTARGET
shall provide CURAGEN and the Joint Steering Committee on a timely basis (that is, promptly after generation) with all data, results, reports and other information generated in connection with TOPOTARGET’s development, either alone or in
permitted collaboration with any Third Party(ies), of any Collaboration Products outside the Territory, including without limitation all data and information relating to any TOPOTARGET Clinical Studies. TOPOTARGET shall promptly inform the Joint
Steering Committee regarding all significant developments and issues in connection with any such clinical studies of Collaboration Products that may arise from time to time. 
  
 (d) Notwithstanding the foregoing, the Joint Steering Committee shall have the right to require TOPOTARGET
to terminate, for reasonable cause, any clinical trial of a Collaboration Product. The Parties acknowledge and agree that for purposes of this Section 8.4(d), reasonable cause shall include, without limitation, the Joint Steering Committee’s
reasonable determination that [*************************************************]. 
  
 8.5 Use of CURAGEN Clinical Data. Notwithstanding Section 12.1, and subject to compliance with Section 9.9, TOPOTARGET shall be permitted to use, and to allow its Affiliates and licensees to use,
clinical data and information generated or obtained by CURAGEN or resulting from clinical trials paid for by CURAGEN hereunder (“CURAGEN Clinical Data”) with respect to TOPOTARGET’s efforts to obtain regulatory approval for
Collaboration Products outside the Territory so long as TOPOTARGET informs CURAGEN of 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	45









 
any such intended use, limits the extent of any concomitant disclosure to the maximum extent possible, and provides copies to CURAGEN of any documents which
embody any such CURAGEN clinical data and/or information which are to provided to any Third Party. TOPOTARGET hereby unconditionally guarantees the performance of any of its Affiliates and licensees with respect to the rights granted hereunder.

  
 8.6 Reporting. 
  
 (a) The Joint Steering Committee shall establish data
collection and data sharing standards, which will include without limitation, standards regarding the collection and provision to each Party of all safety data. The Parties shall use best efforts to adhere to such data collection standards.

  
 (b) In the event of a change of control of
TOPOTARGET (whether through merger, consolidation, acquisition (directly or indirectly) of stock representing 50% or more of the outstanding voting stock or other of its equity securities, sale of all or substantially all of its assets, or
otherwise) which results in control of TOPOTARGET by any Third Party that, in the good faith determination of CURAGEN, is a competitor of CURAGEN and is developing an HDAC inhibitor, CURAGEN shall not be required to include in any report furnished
by CURAGEN pursuant to this Agreement, or provide to any representative of TOPOTARGET (or any successor thereto), any information that CURAGEN, acting in good faith, determines to be competitively sensitive or enabling information. Nothing in this
provision should be understood to restrict CURAGEN’s right to cross-reference regulatory filings and dossiers pursuant to Section 8.3 or to limit any obligation pursuant to Section 8.7 hereof. 
  
 (c) In the event of a change of control of CURAGEN (whether
through merger, consolidation, acquisition (directly or indirectly) of stock representing 50% or more of the outstanding voting stock or other of its equity securities, sale of all or substantially all of its assets, or otherwise) which results in
control of CURAGEN by any Third Party that, in the good faith determination of TOPOTARGET, is a competitor of TOPOTARGET and is developing an HDAC inhibitor, TOPOTARGET shall not be required to include in any report furnished by TOPOTARGET pursuant
to this Agreement, or provide to any representative of CURAGEN (or 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	46









 
any successor thereto), any information that TOPOTARGET, acting in good faith, determines to be competitively sensitive or enabling information. Nothing in
this provision should be understood to restrict TOPOTARGET’s right to cross-reference regulatory filings and dossiers pursuant to Section 8.3 or to limit any obligation pursuant to Section 8.7 hereof. 
  
 8.7 Adverse Events. 
  
 (a) The Parties shall develop standard operating procedures
for the investigation and reporting of adverse events concerning Collaboration Products. The Parties shall immediately implement such agreed procedures and shall provide each other in a time frame consistent with regulatory obligations with any
information which has become available to them and which is relevant to the safe use of the Collaboration Products or which is required by local law in all countries where the Collaboration Products are marketed or are in clinical trials.

  
 (b) Both as an integral part of the
procedures referred to in (a) above and as a separate obligation under this Agreement, each Party shall notify the other Party of each report of a “serious adverse event” (as defined below). The notification shall be made in the
appropriate format prescribed in the said procedures by the fastest available means. The responsibility for submitting any such report to health registration authorities in particular countries shall be stipulated in the said procedures. Upon the
request of one Party, the other Party shall promptly investigate a serious adverse event and shall promptly submit follow-up reports upon the receipt of new information. The said procedures are subject to such changes as may be adjudged necessary or
as shall be required by applicable law. For the purposes of this provision, “serious adverse event” shall mean any adverse drug experience occurring at any dose that results in any of the following outcomes: death, a life-threatening
adverse drug experience (i.e. placing the patient or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred), inpatient hospitalization or prolongation of existing hospitalization, a persistent or
significant disability/incapacity, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse event when, based upon appropriate
medical judgment, they may jeopardize the 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	47









 
patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed above. 
  
 (c) Each Party shall promptly notify the other of, and
provide copies of, any proposed, pending, threatened or completed governmental action concerning adverse events which might affect any Collaboration Product. 
  

(d) Each Party shall cooperate with the other Party to comply with any new applicable regulatory requirements on adverse drug event
reporting which may from time to time be imposed in the countries where a Collaboration Product is developed, tested or marketed. 
  
 8.8 Trademarks. CURAGEN shall designate the generic name of any Collaboration Product and register such name with USAN (United States
Adopted Name/International Nonproprietary Name). CURAGEN shall market the Collaboration Products throughout the Territory under trademarks (collectively, the “CURAGEN Trademarks”) selected by CURAGEN, which shall not use, incorporate or be
confusingly similar to any trademark, trade name, or service mark of TOPOTARGET in existence as of the later of the Effective Date or the registration date of any such CURAGEN Trademark. CURAGEN shall own all right, title and interest in and to such
CURAGEN Trademarks and shall bear all costs and expenses of registering, and maintaining the registration of, same, within or outside the Territory. TOPOTARGET may not use any marks similar to the CURAGEN Trademarks without the prior written consent
of CURAGEN except as expressly set forth in Section 7.5 hereof. TOPOTARGET has retained the right to market the Collaboration Products outside the Territory and may select trademarks for such purposes in TOPOTARGET’s discretion, subject to the
restrictions set forth above (collectively, the “TOPOTARGET Trademarks”). TOPOTARGET shall own all right, title and interest in and to such TOPOTARGET Trademarks and shall bear all costs and expenses of registering, and maintaining the
registration of, same. CURAGEN may not use any marks similar to the TOPOTARGET Trademarks without the prior written consent of TOPOTARGET. 
  
 8.9 Publications. Each Party shall be free to publish and/or make presentations concerning the results of its development efforts under this
Section 8, subject to its compliance 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	48









 
with this Section 8.9 and with any other guidelines established by the Joint Steering Committee. Each Party shall deliver to the other Party and the Joint
Steering Committee copies of all articles and papers to be published, and reasonably detailed abstracts of presentations to be made, concerning such subject matter at least 30 days prior to the anticipated submission or presentation date thereof.
The non-publishing Party shall have 30 days after receipt of said copies to object to such proposed publication or presentation because Confidential Information of such non-publishing Party is contained in the proposed publication or presentation,
because such proposed publication or presentation would disclose Know-How or the proprietary and confidential details of an Invention for which such non-publishing Party has a license under this Agreement and that the Joint Steering Committee has
determined, either generally or in particular, should be the subject of Patent protection. In the event the non-publishing Party makes such objection due to inclusion of the non-publishing Party’s Confidential Information, the Parties shall
negotiate an acceptable version of such proposed publication or presentation. In the event that the non-publishing Party makes such objection due to the need for patent protection, then such publication or presentation shall be delayed for a
reasonable period of time (not to exceed 90 days) during which the Party having responsibility therefore (under Section 6.4) shall file a patent application in the appropriate jurisdiction(s) with respect to such Know-How or Invention. 

 

	9.	MONETARY OBLIGATIONS. 

  
 9.1 License Fee. In partial consideration of the rights and licenses granted to CURAGEN under this Agreement, within 30 days after the
execution of this Agreement CURAGEN shall pay TOPOTARGET a non-refundable, non-creditable one-time license fee in the amount of US$5,000,000. 
  
 9.2 Loan Commitment. In partial consideration of the rights and licenses granted to CURAGEN hereunder, CURAGEN hereby agrees to advance
certain sums to TOPOTARGET as further provided in the Convertible Debenture and Convertible Loan Agreement executed by the Parties and of even date herewith, copies of which are attached hereto in Exhibit H (the “Loan Agreements”).

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	49









 In the event CURAGEN exercises its rights hereunder to terminate this Agreement pursuant to Section 15.3,
CURAGEN shall have the right to accelerate the Loan and make immediate written demand for payment of all amounts due thereunder, and notwithstanding any provision of the Loan Agreements, all amounts due under the Loan shall become due and payable in
cash thirty (30) days after delivery of such written demand for payment. 
  
 9.3 Additional Upfront Payment. In addition to the consideration specified above, in partial consideration of the rights and licenses granted to CURAGEN under this Agreement, CURAGEN shall pay to
TOPOTARGET a non-refundable, non-creditable payment of US$5,000,000 on Phase II Initiation in the United States for the First Product, provided that such event occurs by [*************]. Otherwise, the amount payable pursuant to this Section 9.3
shall be reduced by [***********************************************************]. 
  
 9.4 Take Up Fee. 
  
 (a) The Parties acknowledge and agree that during the Research Program, the Parties may identify Future Products. In order to retain its rights to any such Future Products, CURAGEN shall pay to TOPOTARGET a
non-refundable, non-creditable fee (the “Take Up Fee”) for each distinct Future Product within the earlier of (i) thirty (30) days after the first acceptance of the filing of an IND for such Future Product anywhere in the world or (ii)
twenty-four months following the expiration or termination of the Research Term. The Take Up Fee shall be US$500,000 for each of the first two Future Products and US$1,000,000 for each Future Product thereafter. 
  
 (b) In addition, for each Future Product for which the Take
Up Fee has not been paid within twelve (12) months following the expiration or termination of the Research Term, in order to retain its rights to such Future Product, CURAGEN shall pay to TOPOTARGET a non-refundable fee of [***************] (a
“Maintenance Fee”) on or before such twelve-month anniversary, which amount shall be fully creditable against any Take Up Fee subsequently paid for the same Future Product. Failure to pay any such amount when due shall cause such Future
Product and its Back-Up Products to be removed from operation of this Agreement as provided in Section 7.2(c). 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	50









 9.5 Development Milestone Payments by CURAGEN. 
  
 (a) In partial consideration of the rights and licenses
granted to CURAGEN under this Agreement, CURAGEN shall pay TOPOTARGET the following non-refundable, non-creditable milestone payments upon the first occurrence of each event set forth below with respect to the First Product, whether such occurrence
is achieved by CURAGEN or its Affiliates or its Sublicensees (or TOPOTARGET with respect to Phase II Initiation), so long as such event occurs prior to the expiration of the Royalty Term for the First Product: 
  
 (i) US$3,000,000 upon Phase II initiation for such First
Product; provided, however, that such amount shall be reduced by [***************]; 
  
 (ii) [***************] upon Phase III Initiation for the First Product; 
  
 (iii) [***************] upon acceptance of filing of the NDA for the First Product by the FDA; 

 
 (iv) [***************] upon acceptance of filing of the
first NDA for the First Product by relevant authorities in Japan; 
  
 (v) [***************] upon First Commercial Sale of the First Product in the United States; and 
  
 (vi) [***************] upon First Commercial Sale of the First Product in Japan. 
  
 Each of the foregoing payments shall be made within 30 days after achievement of such
milestone. For the avoidance of doubt, after CURAGEN has made any of the foregoing payments with respect to the First Product, CURAGEN shall have no further obligation to make the same milestone payment with respect to the First Product, or with
respect to any other product which is an alternative formulation of the First Product, regardless of the number of clinical trials, NDAs or regulatory approvals for such First Product. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	51









 (b) In partial consideration of the rights and licenses granted to CURAGEN under this
Agreement, CURAGEN shall pay TOPOTARGET the following non-refundable, non-creditable milestone payments upon the first occurrence of each event set forth below with respect to each Future Product, whether such occurrence is achieved by CURAGEN or
its Affiliates or its Sublicensees so long as such event occurs prior to the expiration of the relevant Royalty Term: 
  
 (i) US$3,000,000 upon Phase II Initiation for such Future Product; provided, however, that such amount shall be reduced by
[****************************************************************]; 
  
 (ii) [************] upon Phase III Initiation for the Future Product; 
  
 (iii) [************] upon acceptance of filing of the first NDA for the Future Product by the FDA; 
  
 (iv) [************] upon acceptance of filing of the first
NDA for the Future Product by relevant authorities in Japan; 
  
 (v) [************] upon First Commercial Sale of the Future Product in the United States; and 
  
 (vi) [************] upon First Commercial Sale of the Future Product in Japan. 
  
 Each of the foregoing payments shall be made within 30 days after achievement of such
milestone. For the avoidance of doubt, after CURAGEN has made any of the foregoing payments with respect to any Future Product, CURAGEN shall have no further obligation to make the same milestone payment with respect to such Future Product, or with
respect to any other Future Product that is an alternative formulation of such Collaboration Product for which milestones have been paid pursuant to Section 9.5(a) or (b) hereof, regardless of the number of clinical trials, NDAs or regulatory
approvals for any such Future Product. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	52









 (c) If CURAGEN notifies TOPOTARGET that it is developing both a lead Collaboration
Product and a Back-Up Product in the Territory, CURAGEN shall be obligated to pay only one set of milestones as set forth in (a) or (b) above until the acceptance for filing of an NDA on the second of such two Collaboration Products in the United
States or Japan, at which time CURAGEN shall pay: (i) the specified milestone for such event; and (ii) to the extent such payments were not previously made or applicable, all preceding milestones which have been met for such second Collaboration
Product, plus interest on such amounts at an annual percentage rate equal to [*********(***)] per year or the highest rate allowed under applicable law, whichever is lower, compounded annually from the date the milestone would have been met until
the payment is made; and (iii) the remaining milestones for such second Collaboration Product when the specified events are achieved. 
  
 (d) If the development or commercialization of a Collaboration Product is abandoned during the term of this Agreement for any specific,
medical or commercial reason after one or more of the milestone payments specified in (a) or (b) above are made, and a Back-Up Product is developed to replace the abandoned Collaboration Product, then no milestone payment shall be required with
respect to the Back-Up Product to the extent that such milestone payment has already been made with respect to the abandoned Collaboration Product. 
  
 9.6 Royalties. 
  
 (a) In partial consideration of the rights and licenses granted to CURAGEN under this Agreement, CURAGEN shall pay TOPOTARGET a royalty on
Net Sales of each Covered Product, commencing on the First Commercial Sale of each such Covered Product by or on behalf of CURAGEN, its Affiliates or its Sublicensees in each country in the Territory and continuing during the Royalty Term for such
Covered Product for such country, in an amount calculated by multiplying the applicable percentage (i.e., the royalty payable thereon) from the following chart by the aggregate Net Sales of each such Covered Product throughout the Territory during
each calendar year (or portion thereof) during the term of this Agreement: 
  

			
	 Increment of Annual Net Sales (“ANS”) of Subject
Covered Product In the Territory Achieved During
Calendar Year

	  	Royalty Payable
Thereon


	 [************]
	  	[*****]
		
	 [************]
	  	[*****]
		
	 [************]
	  	[*****]
		
	 [************]
	  	[*****]
		
	 [************]
	  	[*****]
		
	 [************]
	  	[*****]

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	53









 (b) CURAGEN’s obligation to pay royalties with respect to each Covered Product in
each country in the Territory shall expire upon the expiration of the Royalty Term with respect to such Covered Product in such country. 
  
 (c) The obligation to pay royalties to TOPOTARGET under this Section 9.6 is imposed only once with respect to the same unit of Covered
Product, regardless of the number of Patents pertaining thereto. 
  
 9.7 Third Party Royalties. 
  
 (a) CURAGEN, at its sole expense, shall pay all license fees, milestones and earned royalties owing to any Third Party with respect to patents regarding the composition or method of manufacture of the HDAC Inhibitor component of any
Collaboration Product (“Third Party HDAC Patents”) that CURAGEN determines, in its reasonable business judgment, are necessary in order to develop, make, have made, use, sell, offer for sale, have sold or export any such Collaboration
Product in the Territory (collectively, “Third Party HDAC Royalties”). 
  
 (b) CURAGEN shall be entitled to a credit against royalties due to TOPOTARGET under this Agreement for any Covered Product in an amount
equal to [******] 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	54









 
of the aggregate Third Party HDAC Royalties paid by CURAGEN in any country in the Territory with respect to the relevant Covered Product; provided,
however, that the application of such credit shall not reduce the royalties payable by CURAGEN under this Agreement for such Covered Product with respect to any given calendar quarter by more than [******]. Notwithstanding the foregoing, if
CURAGEN, in lieu of or in addition to any Third Party HDAC Royalties, is required to pay an award of damages or a settlement amount in the form of a reasonable royalty based on sales during any period of previous infringement of any Third Party HDAC
Patents (as opposed to the on-going payment of a running royalty), then such payment shall be allocated to the several calendar quarters during such period of infringement, and the limits set forth in the previous sentence shall apply to each
portion of such payment allocated to a specific quarter and not to such payment as a whole, and an appropriate credit shall be permitted so long as no quarterly payment is reduced by more than [******]. 
  
 (c) Each Party, at its sole expense, shall pay all license
fees, milestones and earned royalties owing to any Third Party as a result of the licensing of Patents other than Third Party HDAC Patents (“Other Third Party Patents”), that the Joint Steering Committee determines, in its reasonable
business judgment, are necessary in order to develop, make, have made, use, sell, offer for sale, have sold or export any Collaboration Product in its respective territory (collectively, “Other Third Party Royalties”). All such amounts
that are due with respect to a particular country shall be borne by the Party in whose territory such country falls hereunder. All other amounts shall be allocated based on the ratio of affected sales in each Party’s territory, as mutually
agreed by the Parties. 
  
 (d) Each Party shall
be entitled to a credit against royalties due to the other Party under this Agreement on any Covered Product from CURAGEN pursuant to Section 9.6, or on any Collaboration Product from TOPOTARGET pursuant to Section 9.9. in each case in an amount
equal to [******] of the aggregate Other Third Party Royalties paid by such Party in any country in its territory; provided, however, that the application of such credit shall not reduce the royalties payable by such Party under this
Agreement for such Covered Product or Collaboration Product, as relevant, with respect to any given calendar quarter, after any adjustment permitted to CURAGEN pursuant to (b) above where CURAGEN has paid both Third Party HDAC Royalties 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	55









 
and Other Third Party Royalties, by more than [******]. Notwithstanding the foregoing, if such Party, in lieu or in addition to any Other Third Party
Royalties, is required to pay an award of damages or a settlement amount in the form of a reasonable royalty based on sales during any period of previous infringement of Other Third Party Patents (as opposed to the on-going payment of a running
royalty), then such payment shall be allocated to the several calendar quarters during such period of infringement, and the limits set forth in the previous sentence shall apply to each portion of such payment allocated to a specific quarter and not
to such payment as a whole, and an appropriate credit shall be permitted so long as no quarterly payment is reduced by more than [******]. 
  
 9.8 Royalty Increases. Notwithstanding any provision herein to the contrary, TOPOTARGET shall have the right, at its sole option, to share
in the expenses of developing any Collaboration Product in the Territory and increase the royalties due to TOPOTARGET on sales of the resulting Covered Product(s) in the Territory as follows: 
  
 (a) TOPOTARGET must notify CURAGEN of its desire to exercise
its option to increase royalties pursuant to this Section 9.8 by delivering written notice thereof to CURAGEN prior to Phase III Initiation of the relevant Collaboration Product; 
  
 (b) TOPOTARGET shall pay CURAGEN [*******(****)] of the development costs incurred by CURAGEN, its
Affiliates and Sublicensees with respect to such Collaboration Product, including any Research Program funding provided by CURAGEN under Section 5.3 and excluding any milestones paid under Section 9, prior to the date of such notice, within thirty
(30) days of receipt of an invoice from CURAGEN for such costs; 
  
 (c) TOPOTARGET shall, from and after the date of such notice, be responsible for [*******(****)] of all future development costs for such Collaboration Product and shall make payments therefore within ten (10) days of
receipt of monthly invoices for such expenses from CURAGEN; and 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	56









 (d) Subject to TOPOTARGET making all payments specified above in full, the royalties on
the relevant Covered Product(s) shall thereafter be as follows instead of as stated in Section 9.6: 
  

			
	 Increment of Annual Net Sales (“ANS”) of Subject
Covered Product In the Territory Achieved During
Calendar Year

	  	Royalty Payable
Thereon


	 [********************]
	  	[*****]
		
	 [********************]
	  	[*****]
		
	 [********************]
	  	[*****]
		
	 [********************]
	  	[*****]
		
	 [********************]
	  	[*****]
		
	 [********************]
	  	[*****]

  
 9.9
Royalties to CURAGEN. In the event that TOPOTARGET exercises its rights as provided in Section 8.5 to use CURAGEN Clinical Data, and makes any material use of any CURAGEN Clinical Data in connection with any registration or marketing of
any Collaboration Product in the TOPOTARGET Territory, whether by itself or in collaboration with any Third Party, TOPOTARGET shall notify CURAGEN of such use and shall become obligated to make royalty payments to CURAGEN as partial consideration
for access to such clinical data and the investment made by CURAGEN therein. Unless otherwise provided in Section 15.6(c), royalty payments shall be owed to CURAGEN at the rates specified in Section 9.6 on the Net Sales in the TOPOTARGET Territory
of each Collaboration Product with respect to which such CURAGEN Clinical Data was used or whose use or sale in the relevant country is covered by one or more Valid Claims of CURAGEN Licensed Technology or the CURAGEN Collaboration Technology. The
Parties hereby agree that, unless a shorter period is otherwise provided in Section 15.2, such payments shall continue in each country for the duration of any Royalty Term 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	57









 
for a corresponding Covered Product in such country, notwithstanding the fact that such royalties are being provided as consideration for access to rights
which are not necessarily patent rights. All such payments shall be subject to the Net Sales definition as if each such Collaboration Product was a Covered Product therein, and shall be subject to the Third Party Royalty provisions of Section 9.7(c)
and (d) and the reporting and payment provisions as provided in Section 10, with the rights and obligations of the Parties under such definition and such Sections reversed. Notwithstanding the foregoing, royalty payments due to CURAGEN under this
Section 9.9 during any royalty period shall be applied as a credit against any milestones and royalties owed by CURAGEN to TOPOTARGET on any or all Collaboration Products during the relevant royalty period; provided, however, that if any
credit cannot be fully utilized in any royalty period, it shall be carried forward into future periods until exhausted, and such future credits shall accrue interest at the rate of [********(****)] compounded annually. Other than as provided in
Article 15, TOPOTARGET shall not be obligated to submit actual payment of any royalty calculated to be due hereunder to CURAGEN. 
  

	10.	PAYMENTS AND REPORTS. 

  
 10.1 Payment. Except as otherwise provided in this Agreement, all royalty and other payments due hereunder shall be paid quarterly within 45
days after the end of each calendar quarter. Each such payment shall be accompanied by a statement, Covered Product-by-Covered Product and country-by-country, of the amount of Net Sales during such quarter and the amount of royalties due on such Net
Sales. 
  
 10.2 Mode of Payment. CURAGEN shall make
all payments required under this Agreement as directed by TOPOTARGET from time to time, in U.S. Dollars (except as provided in Section 10.6). All royalties due hereunder shall first be determined in the currency of the country in which the Covered
Products in question were sold and then converted into equivalent U.S. funds. The exchange rate for such conversion shall be that rate quoted in The Wall Street Journal on the last business day of the applicable reporting period. 
  
 10.3 Records Retention. CURAGEN, its Affiliates and its
Sublicensees shall keep complete and accurate records pertaining to the sale of Covered Products in the Territory and 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	58









 
covering all transactions from which Net Sales are derived for a period of three calendar years after the year in which such sales occurred, and in
sufficient detail to permit TOPOTARGET to confirm the accuracy of royalty payments due hereunder. 
  
 10.4 Audit Request. At the request and expense (except as provided below) of TOPOTARGET, CURAGEN, its Affiliates and its Sublicensees shall
permit an independent, certified public accountant appointed by TOPOTARGET and reasonably acceptable to CURAGEN, at reasonable times and upon reasonable notice, to examine those records and all other material documents relating to or relevant to Net
Sales in the possession or control of CURAGEN, its Affiliates or its Sublicensees, for a period of three calendar years after the year in which such royalties have accrued. The results of any such examination shall be made available to both Parties.
If, as a result of any inspection of the books and records of CURAGEN, its Affiliates or its Sublicensees, it is shown that CURAGEN’s royalty payments under this Agreement were less than the amount which should have been paid, then CURAGEN
shall make all payments required to eliminate any discrepancy revealed by said inspection within 45 days after TOPOTARGET’s demand therefor. Furthermore, if the aggregate royalty payments CURAGEN made were less than [********] of the amount
which should have been paid made during the period in question, CURAGEN shall also reimburse TOPOTARGET for the reasonable out-of-pocket cost of such inspection. 
  
 10.5 Taxes. In the event that CURAGEN is required to withhold any tax to the tax or revenue authorities in any
country in the Territory in connection with any payment to TOPOTARGET due to the laws of such country, such amount shall be deducted from the royalty or other payment to be made by CURAGEN, and CURAGEN shall notify TOPOTARGET and promptly furnish
TOPOTARGET with copies of any tax certificate or other documentation evidencing such withholding. Each Party agrees to cooperate with the other Party in claiming exemptions from such deductions or withholdings under any agreement or treaty from time
to time in effect. 
  
 10.6 Blocked Currency. If by
law, regulations or fiscal policy of a particular country in the Territory, remittance of royalties in United States Dollars is restricted or forbidden, written 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	59









 
notice thereof shall promptly be given to TOPOTARGET, and payment of the royalty shall be made by the deposit thereof in local currency to the credit of
TOPOTARGET in a recognized banking institution reasonably designated by TOPOTARGET by written notice to CURAGEN. When in any country in the Territory the law or regulations prohibit both the transmittal and the deposit of royalties on sales in such
country, royalty payments shall be suspended for as long as such prohibition is in effect and as soon as such prohibition ceases to be in effect, all royalties that CURAGEN would have been under an obligation to transmit or deposit but for the
prohibition shall forthwith be deposited or transmitted, to the extent allowable. 
  

	11.	MANUFACTURING. 

  
 11.1 Manufacturing Responsibility. 
  
 (a) Until the completion of any transfer of responsibility to CURAGEN as provided in (b) below, TOPOTARGET shall use reasonable commercial
efforts, to the extent it is reasonably capable of doing so, to supply CURAGEN, itself or through TOPOTARGET’s use of Third Party manufacturers, with CURAGEN’s requirements for Collaboration Products for use under this Agreement. The cost
to CURAGEN of Collaboration Products supplied for use in the Development Program for studies conducted at CURAGEN’s expense, including without limitation studies conducted under the CRADA so long as CURAGEN has rights to use all resulting data
in the Territory, shall be [********] of the invoiced price TOPOTARGET pays therefor or [********] of TOPOTARGET’s fully burdened cost of goods sold (which cost shall not include process development costs). Any supply for commercial purposes
shall be at a price to be agreed for each Collaboration Product, assuring a reasonable profit to TOPOTARGET. TOPOTARGET shall manufacture Collaboration Products, or shall cause TOPOTARGET’s Third Party manufacturers to manufacture same, in
accordance with current Good Manufacturing Practices under 21 C.F.R. 210 and 211 and all applicable laws, rules and regulations. TOPOTARGET shall provide CURAGEN with copies of, or permission to reference, as appropriate, any Drug Master File or
similar filing (“DMF”) made by TOPOTARGET with respect to any Collaboration Product, and shall not withdraw or modify any such DMF without prior written notice to CURAGEN. TOPOTARGET shall promptly notify CURAGEN of any 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	60









 
event which could materially affect TOPOTARGET’s ability to supply Collaboration Product to CURAGEN hereunder, and shall provide to CURAGEN copies of
any correspondence with any regulatory authority that relates to its manufacturing activities with respect to Collaboration Products. 
  
 (b) Upon request of CURAGEN delivered at any time after the conclusion of the Research Term, TOPOTARGET shall give reasonable
consideration to and agrees to discuss with CURAGEN in good faith the possibility of transferring responsibility for manufacturing Collaboration Products for use by CURAGEN from TOPOTARGET to CURAGEN. Any such proposal must take into consideration
TOPOTARGET’s own needs for a reliable and economical supply of Collaboration Products. 
  
 11.2 Negotiation, Execution of Supply Agreement. Promptly upon request by CURAGEN, the Parties shall negotiate, diligently and in good faith, and execute a supply agreement (the “Supply
Agreement”) pursuant to which TOPOTARGET shall sell to CURAGEN, and CURAGEN shall purchase from TOPOTARGET, CURAGEN’s commercial requirements of Collaboration Products as provided in Section 11.1(a) above. 
  
 11.3 Cost of Manufacturing and Related Activities. Except as
expressly provided to the contrary in this Section 11, each Party shall be solely responsible for all of the costs and expenses it has incurred before, or incurs after, the Effective Date, in connection with the manufacture of any Collaboration
Product. 
  
 11.4 Manufacturing Liaisons. Each Party
shall have the right to appoint one employee or consultant to act as a liaison between TOPOTARGET’s and CURAGEN’s relevant manufacturing teams. Each Party shall inform the other Party’s liaison regarding the status of such
Party’s manufacturing-related efforts (including scale-up, process development and actual manufacturing) under this Agreement and/or the Supply Agreement, and the two liaisons shall coordinate such efforts with the Parties’ performance of
their other respective obligations under this Agreement and/or the Supply Agreement. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	61










	12.	CONFIDENTIALITY. 

  
 12.1 Confidentiality; Exceptions. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties
agree that, during the term of this Agreement and for five years thereafter each Party, its Affiliates and its Sublicensees, if any (collectively, a “receiving Party”), shall use their best efforts to keep completely confidential, shall
not publish or otherwise disclose and shall not use for any purpose other than the performance of this Agreement both the financial terms of this Agreement and any information furnished to it by the other Party, its Affiliates or its Sublicensees,
if any (collectively, a “disclosing Party”), or developed under or in connection with the Research Program or any product development efforts pursuant to this Agreement (and shall ensure that its and its Affiliates’ and its
Sublicensees’ respective directors, officers, employees or agents do likewise), except to the extent that it can be established by the receiving Party by competent proof that such information: (i) is, or hereafter becomes, generally available
to the public other than by reason of any default by the receiving Party with respect to its confidentiality obligations hereunder; or, (ii) with respect to information disclosed by one Party to the other Party (a) was already known to the receiving
Party at the time of disclosure by the disclosing Party; (b) was lawfully disclosed to the receiving Party by a Third Party who was not in default of any confidentiality obligation to the disclosing Party; or (c) is independently developed by or for
the receiving Party without reference to or reliance upon the information furnished by the disclosing Party (all such information to which none of the foregoing exceptions applies, “Confidential Information”). 
  
 12.2 Exclusions to Confidentiality. The restrictions contained
in Section 12.1 shall not apply to any Confidential Information in the hands of a receiving Party to the extent that it (i) is submitted by the receiving Party to governmental authorities to facilitate the issuance of marketing approvals for a
Collaboration Product in accordance with the terms of this Agreement, provided that reasonable measures shall be taken to assure confidential treatment of such information, if practicable; (ii) is provided by a Party to any Third Party under
appropriate terms and conditions, including confidentiality provisions equivalent to those in this Agreement, for consulting, manufacturing development, manufacturing, external testing, marketing trials and sublicensing or potential sublicensing in
accordance with the terms hereof; or (iii) is otherwise required to be disclosed in compliance with applicable laws or regulations (including, without 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	62









 
limitation, to comply with any governmental or stock exchange disclosure requirements) or an order by a court or other regulatory body having competent
jurisdiction; provided, however, that if a receiving Party is required to make any such disclosure of the disclosing Party’s Confidential Information such receiving Party shall, except where impracticable for necessary disclosures (for
example to physicians conducting studies or to health authorities), give reasonable advance notice to the other Party of such disclosure requirement and, except to the extent inappropriate in the case of patent applications or otherwise, will use
its best efforts to secure confidential treatment of such Confidential Information required to be disclosed. 
  
 12.3 Injunctive Relief. The Parties acknowledge that monetary damages alone would not adequately compensate the disclosing Party in the
event of a breach by the receiving Party of this Section 12, and that, in addition to all other remedies available to the disclosing Party under this Agreement, at law or in equity, it shall be entitled to injunctive relief for the enforcement of
its rights under this Section 12, without the posting of a bond or other security, and to an accounting of profits made during the period of any breach of the receiving Party’s obligations under this Section 12. 
  

	13.	INTELLECTUAL PROPERTY. 

  
 13.1 Patent Enforcement. 
  
 (a) Each Party shall notify the other promptly after such Party becomes aware of any alleged infringement in the Field of any Patent
licensed to either Party under this Agreement in any country. CURAGEN shall have the first right, but not the duty, to institute patent infringement actions against Third Parties with respect to any such alleged infringement in the Field and in the
Territory. CURAGEN shall take all such actions under this Section 13.1(a) (other than with respect to a Patent included solely in the CURAGEN Collaboration Technology) in reasonable consultation with TOPOTARGET and shall keep TOPOTARGET apprised as
to the status of any such infringement action CURAGEN institutes. TOPOTARGET shall execute all reasonable, necessary and proper documents and take such actions, at CURAGEN’s request and expense, as shall be appropriate to allow CURAGEN to
institute and prosecute infringement actions under this Section 13.1(a). 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	63









 (b) The costs and expenses of bringing and maintaining any infringement action under
Section 13.1(a) shall be borne solely by CURAGEN. 
  
 (c) Any award or compensation (including the fair market value of non-monetary compensation) paid by Third Parties as a result of any infringement action brought by CURAGEN under Section 13.1(a) (whether by way of settlement or otherwise)
shall be allocated first to reimbursement of CURAGEN for all expenses incurred by it in connection with such action. Any remaining award or compensation shall be allocated to the Parties in the following proportions:
[*************************************************]. 
  
 (d) In the event CURAGEN elects not to, or fails to, exercise its rights under Section 13.1(a) with respect to any alleged infringement of a Patent licensed to CURAGEN under this Agreement (i.e., excluding any Patent included solely in the
CURAGEN Collaboration Technology) within 120 days after receiving notice thereof, TOPOTARGET shall have the right, but not the duty, to institute patent infringement actions against Third Parties with respect to any such alleged infringement.
TOPOTARGET shall take all such actions under this Section 13.1(d) in reasonable consultation with CURAGEN and shall keep CURAGEN apprised as to the status of any such infringement action TOPOTARGET institutes. CURAGEN shall execute all reasonable,
necessary and proper documents and take such actions, at TOPOTARGET’s request and expense, as shall be appropriate to allow TOPOTARGET to institute and prosecute infringement actions under this Section 13.1(d). The costs and expenses of
bringing and maintaining any infringement action under this Section 13.1(d) shall be borne solely by TOPOTARGET, and TOPOTARGET shall be entitled to retain any award or compensation (including the fair market value of non-monetary compensation) paid
by Third Parties as a result of any such action. 
  
 13.2
Infringement Actions by Third Parties. 
  
 (a) Each Party shall notify the other Party promptly in writing of any claim of, or action for, infringement of any Patents owned or licensed by Third Parties which is threatened, made or brought against either Party by reason of either
Party’s performance of its 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	64









 
obligations under this Agreement or manufacture, use or sale of any Collaboration Products in the Territory in the Field. 
  
 (b) In the event that such an action for infringement is
commenced solely against a Party or both Parties jointly and/or any of their respective Affiliates or Sublicensees, as the case may be, with respect to any Collaboration Product developed and commercialized by CURAGEN, its Affiliates and/or
Sublicensees, CURAGEN shall defend such action at its own expense, and TOPOTARGET hereby agrees to assist and cooperate with CURAGEN to the extent necessary in the defense of such suit, in accordance with Section 13.2(c). CURAGEN shall have the
right to settle any such action or consent to an adverse judgment thereto, and TOPOTARGET’s consent shall not be required unless such settlement or consent: (i) imposes any material obligation on TOPOTARGET (including under Section 13.2(d)), or
(ii) materially impairs TOPOTARGET’s rights in or to any TOPOTARGET Licensed Technology, TOPOTARGET Collaboration Technology, CURAGEN Collaboration Technology and/or Joint Collaboration Technology, in which event TOPOTARGET’s consent shall
not be unreasonably withheld or delayed. 
  
 (c)
The costs of defending any infringement action with respect to a Collaboration Product developed and commercialized by CURAGEN, its Affiliates and/or Sublicensees shall be borne solely by CURAGEN. 
  
 (d) Subject to Section 9.6(b), during the pendency of any
such action, CURAGEN shall continue to pay all royalties due hereunder and CURAGEN shall be fully liable for the payment of any award for damages, or any amount due pursuant to any settlement entered into by CURAGEN, to the extent that any such
action pertains to a Collaboration Product developed and commercialized by CURAGEN and/or its Affiliates or Sublicensees. 
  
 (e) Except to the extent that the provisions of Section 13.1 shall apply to any portion thereof, CURAGEN shall retain any award or
compensation (including the fair market value of non-monetary compensation) received by CURAGEN as a result of any such action (i.e., as a result of a counterclaim). 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	65









 (f) In the event that such an action for infringement is commenced solely against a Party
or both Parties jointly and/or any of their respective Affiliates or sublicensees, as the case may be, with respect to any Collaboration Product developed and commercialized by TOPOTARGET, its Affiliates and/or sublicensees, TOPOTARGET shall defend
such action at its own expense, and CURAGEN hereby agrees to assist and cooperate with TOPOTARGET to the extent necessary in the defense of such suit, in accordance with Section 13.2(g). TOPOTARGET shall have the right to settle any such action or
consent to an adverse judgment thereto, and CURAGEN’s consent shall not be required unless such settlement or consent: (i) imposes any material obligation on CURAGEN (including under Section 13.2(h)), or (ii) materially impairs CURAGEN’s
rights in or to any TOPOTARGET Licensed Technology, TOPOTARGET Collaboration Technology, CURAGEN Collaboration Technology and/or Joint Collaboration Technology, in which event CURAGEN’s consent shall not be unreasonably withheld or delayed.

  
 (g) The costs of defending any infringement
action with respect to a Collaboration Product developed and commercialized by TOPOTARGET, its Affiliates and/or sublicensees shall be borne solely by TOPOTARGET. 
  
 (h) During the pendency of any such action, TOPOTARGET shall continue to pay any royalties due hereunder.
TOPOTARGET shall be fully liable for the payment of any award for damages, or any amount due pursuant to any settlement entered into by TOPOTARGET, to the extent that any such action pertains to a Collaboration Product developed and commercialized
by TOPOTARGET and/or its Affiliates or sublicensees. 
  
 (i) Except to the extent that the provisions of Section 13.1 shall apply to any portion thereof, TOPOTARGET shall retain any award or compensation (including the fair market value of non-monetary compensation) received by TOPOTARGET as a
result of any such action (i.e., as a result of a counterclaim). 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	66










	14.	INDEMNIFICATION. 

  
 14.1 By CURAGEN. CURAGEN shall indemnify and hold TOPOTARGET and its Affiliates and their respective directors, officers, employees and
agents, harmless from and against any and all liabilities, damages, losses, costs and expenses (including the reasonable fees of attorneys and other professionals and other reasonable litigation expenses) arising out of or resulting from:

  
 (i) any and all product liability claims
resulting from the development and/or commercialization of any Collaboration Product by CURAGEN, its Affiliates or its Sublicensees; and 
  
 (ii) any warranty claims, Collaboration Product recalls or any tort claims of personal injury (including death) or property damage
relating to or arising out of the manufacture, use, distribution or sale of any Collaboration Product by CURAGEN, its Affiliates or its Sublicensees due to any negligence, recklessness or intentional misconduct by, or strict liability of, CURAGEN,
its Affiliates or its Sublicensees, and their respective directors, officers, employees and agents. 
  
 14.2 By TOPOTARGET. TOPOTARGET shall indemnify and hold CURAGEN, its Affiliates and their respective directors, officers, employees and
agents, harmless from and against any and all liabilities, damages, losses, costs and expenses (including the reasonable fees of attorneys and other professionals and other reasonable litigation expenses) arising out of or resulting from:

  
 (i) any and all product liability claims
resulting from the development and/or commercialization of any Collaboration Product by TOPOTARGET, its Affiliates or its licensees (other than CURAGEN); and 
  

(ii) any warranty claims, Collaboration Product recalls or any tort claims of personal injury (including death) or property damage
relating to or arising out of the manufacture, use, distribution or sale of any Collaboration Product by TOPOTARGET, its Affiliates or its licensees (other than CURAGEN) 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	67









 
due to any negligence, recklessness or intentional misconduct by, or strict liability of, TOPOTARGET, its Affiliates or its licensees (other than CURAGEN),
and their respective directors, officers, employees and agents. 
  
 14.3 Notice. In the event that any Person entitled thereto (an “indemnitee”) is seeking indemnification under Section 14.1 or 14.2, such indemnitee shall inform the indemnifying Party of a claim as soon as reasonably
practicable after the indemnitee receives notice of the claim, shall permit the indemnifying Party to assume direction and control of the defense of the claim (including the sole right to settle it at the sole discretion of the indemnifying Party,
provided that such settlement does not impose any material obligation on the indemnitee or the other Party) and shall cooperate as requested (at the expense of the indemnifying Party) in the defense of the claim (including, without limitation,
granting the indemnifying Party limited access to pertinent records and making persons under such indemnitee’s control available for interview and testimony). 
  
 14.4 Complete Indemnification. As the Parties intend complete indemnification, all costs and expenses incurred
by any indemnitee to enforce this Section 14 shall be reimbursed by the indemnifying Party. 
  

	15.	TERM; TERMINATION. 

  
 15.1 Term. This Agreement shall commence as of the Effective Date and, unless sooner terminated as provided hereunder, shall expire upon the
expiration of all Royalty Terms in all countries in the Territory with respect to all Collaboration Products. 
  
 15.2 Effect of Expiration. Following the expiration of the applicable Royalty Term with respect to a Collaboration Product in a country in
the Territory, CURAGEN shall have the royalty-free, perpetual right to continue to make, have made, use, sell, offer for sale, have sold and export such Collaboration Product in such country and following the expiration of the last applicable
Royalty Term with respect to a Collaboration Product in the Territory, TOPOTARGET shall have the royalty-free, perpetual right to continue to make, have made, use, sell, offer for sale, have sold and export such Collaboration Product throughout the


  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	68









 
TOPOTARGET Territory. Following the expiration of the term of this Agreement in its entirety pursuant to Section 15.1, CURAGEN shall have the royalty-free,
perpetual right to continue to make, have made, use, sell, offer for sale, have sold and export all Collaboration Products in all countries in the Territory, and TOPOTARGET shall have the royalty-free, perpetual right to continue to make, have made,
use, sell, offer for sale, have sold and export all Collaboration Products in all countries in the TOPOTARGET Territory. 
  
 15.3 Termination For Cause. Each Party shall have the right to terminate this Agreement, upon notice to the other Party, in the event that:

  
 (a) Such other Party materially defaults with
respect to any of its material obligations under this Agreement and does not cure such default within [*****] days after the receipt of a notice in writing from the non-breaching Party specifying the nature of, and requiring the remedy of, such
default (or, if such default cannot be cured within such [*****]-day period, if the breaching Party does not commence cure within such [*****] day period and thereafter diligently continue actions to cure and actually cure same within a period of
[*************] days following such notice); provided, however, that such right to terminate shall be stayed with respect to alleged payment breaches in the event that during such [*****]-day period, the Party alleged to have been in default
with respect to any payment due hereunder shall have paid all undisputed amounts and shall have initiated dispute resolution in accordance with Section 17.15 with respect to any disputed payment default, which dispute resolution the Parties shall
use their best efforts to have conducted and completed within [*****] months of initiation, and which stay shall last until [*********] days following resolution of any such dispute and determination of what, if any, payments are in default.;
provided, further, that if such payment dispute is not resolved within [*********] months as provided above, in order for the stay to continue, [*****] of any amount then is dispute must be prepaid to the non-breaching Party on or before such
[*****] month date, which prepayment shall be credited against any amount found to be due or repaid within [*****] days following resolution of such dispute to the extent all or any portion of it is determined not to be due upon. resolution of such
dispute. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	69









 Notwithstanding the foregoing, if any such non-payment default is limited to the breaching Party’s obligations with
respect to a particular Collaboration Product and/or a particular country, then any termination of this Agreement under this clause (a) due to such default shall be limited to the breaching Party’s rights under this Agreement with respect to
such Collaboration Product and/or country unless termination in all countries is otherwise expressly provided below. 
  
 Any termination pursuant to this clause (a) shall be without prejudice to any of the non-breaching Party’s other rights under this Agreement, and in addition to any
other remedies available to it by law or in equity; 
  
 (b) The other Party shall have: (i) voluntarily commenced any proceeding or filed any petition seeking relief under the bankruptcy, insolvency or other similar laws of any jurisdiction, (ii) applied for, or consented to, the appointment of
a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for it or for all or substantially all of its property, (iii) filed an answer admitting the material allegations of a petition filed against or in respect
of it in any such proceeding, (iv) made a general assignment for the benefit of creditors of all or substantially all of its assets, (v) admitted in writing its inability to pay all or substantially all of its debts as they become due, or (vi) taken
corporate action for the purpose of effecting any of the foregoing; 
  
 (c) An involuntary proceeding shall have been commenced, or any involuntary petition shall have been filed, in a court of competent jurisdiction seeking: (i) relief in respect of the other Party, or of its property,
under the bankruptcy, insolvency or similar laws of any jurisdiction, (ii) the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for such other Party or for all or substantially all of its
property, or (iii) the winding-up or liquidation of such other Party; and, in each case, such proceeding or petition shall have continued undismissed for 60 days, or an order or decree approving or ordering any of the foregoing shall have continued
unstayed, unappealed and in effect for 30 days; 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	70









 (d) In the event that TOPOTARGET becomes administered in bankruptcy, or goes into
insolvent liquidation: 
  
 (i) This Agreement
will remain in effect and binding upon the Parties if the trustee in bankruptcy decides to be subrogated to the rights and obligations of TOPOTARGET according to this Agreement. 
  
 (ii) Notwithstanding the foregoing, in the event that TOPOTARGET becomes administered in bankruptcy or goes
into insolvent liquidation, TOPOTARGET shall, without any further notice and with immediate effect, transfer and assign to CURAGEN (A) all or, at CURAGEN’s option, part of TOPOTARGET’s right, title and interest in the Territory in and to
any of the TOPOTARGET Licensed Technology, the TOPOTARGET Collaboration Technology and the Joint Collaboration Technology, and all data, reports, records, material and other intellectual property owned or controlled by TOPOTARGET, in each case
solely to the extent that they have been licensed to CURAGEN under this Agreement, and in each case solely to the extent related to the Collaboration Products then included in the licenses granted to CURAGEN under this Agreement, (B) the full and
complete right to file patent applications in the name of the CURAGEN, its designee, or in TOPOTARGET’s name at CURAGEN, or its designee’s election, on the aforesaid inventions, discoveries and applications in the Territory; (C) the entire
right, title and interest in and to any Letters Patent which may issue thereon in the United States or in any country in the Territory, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation,
registration and importation of the same; and (D) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above
inventions, discoveries and applications. Such assignment or transfer shall require CURAGEN ́s payment to TOPOTARGET or the estate thereof of an amount equivalent to [*********************************************************], which value shall
be determined by an independent expert chosen by the Danish Institute of State Authorized Public Accountants (in Danish: Foreningen af Statsautoriserede Revisorer) following the methodology outlined on Exhibit I immediately following the
effective date of any such transfer or assignment as provided below, and which amount shall be paid to TOPOGARGET or 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	71









 
the estate thereof in equal monthly installments over [*******(****)] years following the date of determination of such fair market value by such independent
expert. Such transfer or assignment shall be effective as from the date on which the trustee in bankruptcy decides not to be subrogated to the rights and obligations of TOPOTARGET according to this Agreement in accordance with the Danish Act on
Bankruptcy, chapter 7, or when the trustee in bankruptcy or the liquidator decides to transfer or assign the TOPOTARGET Licensed Technology, the TOPOTARGET Collaboration Technology and/or TOPOTARGET’s interest in the Joint Collaboration
Technology to a Third Party. If, however, the trustee in bankruptcy decides to be subrogated to the rights and obligations of TOPOTARGET according to this Agreement, such assignment and transfer shall not occur. 
  
 (iii) In case the assignment or transfer as mentioned in the
previous section cannot be carried out, regardless of the reason, and the trustee in bankruptcy has decided not to be subrogated to the rights and obligations of TOPOTARGET according to this Agreement, CURAGEN shall in any event have a right of
first refusal to purchase the right, title and interest in the Territory in and to any of the TOPOTARGET Licensed Technology, the TOPOTARGET Collaboration Technology and the Joint Collaboration Technology, and all data, reports, records, materials
and other intellectual property owned or controlled by TOPOTARGET that have been licensed to CURAGEN under this Agreement, upon receipt from the trustee in bankruptcy of an offer to purchase such right, title and interest from an independent third
party, at the same price and conditions as such third party has offered. Further, in case neither the assignment nor the right of first refusal can be carried through, CURAGEN shall in such case have a preemption right to purchase the right, title
and interest in the Territory in and to any of the TOPOTARGET Licensed Technology, the TOPOTARGET Collaboration Technology and the Joint Collaboration Technology, and all data, reports, records, materials and other intellectual property owned or
controlled by TOPOTARGET that have been licensed to CURAGEN under this Agreement at a fixed fair market value determined by an independent expert chosen by the Danish Institute of State Authorized Public Accountants (in Danish: Foreningen af
Statsautoriserede Revisorer) if the trustee in bankruptcy or the liquidator decides to transfer or assign the TOPOTARGET Licensed Technology, the TOPOTARGET 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	72









 
Collaboration Technology and/or TOPOTARGET’s interest in the Joint Collaboration Technology or at the latest at the time of winding up of the bankruptcy
estate. CURAGEN shall from the date on which the trustee in bankruptcy decides not to subrogate and until either the right of first refusal or the pre-emption right is exercised be entitled to make any and all necessary payments and take any
necessary actions in order to maintain relevant patents. Further, CURAGEN shall from the date on which the trustee in bankruptcy decides not to subrogate and until either the right of first refusal or the pre-emption right is exercised be entitled
to continue the use of the TOPOTARGET Licensed Technology, the TOPOTARGET Collaboration Technology and the Joint Collaboration Technology subject to continued payment by CURAGEN according to the terms of this Agreement during such period. Any and
all costs, including license payments made after the effective date of the valuation, incurred by CURAGEN according to these rights of CURAGEN, shall be set off against the final purchase amount according to clause (iii) (right of first refusal or
pre-emption right). 
  
 (iv) In the event of any
assignment or transfer to CURAGEN pursuant to clause (ii) CURAGEN shall have no further obligation to pay any milestones or royalties under this Agreement. 
  
 15.4 Termination Without Cause by CURAGEN. Notwithstanding any other provision of this Agreement, after the expiration or termination of the
Research Term, CURAGEN shall have the right to terminate this Agreement, in its entirety or with respect to any particular Collaboration Product and/or country in the Territory, at any time upon three (3) months’ notice in writing to
TOPOTARGET. Termination under this Paragraph shall automatically terminate any and all relevant CURAGEN license rights and relevant sublicenses granted hereunder by CURAGEN. 
  
 15.5 Effect of Termination. 
  

(a) Upon any voluntary termination of any rights or licenses by CURAGEN pursuant to Section 15.4, any and all relevant licenses granted
to CURAGEN hereunder, and all 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	73









 
relevant sublicenses, shall terminate and TOPOTARGET shall thereafter have rights as provided in Section 15.6(a) hereof with respect to such terminated
rights, and shall retain its rights as provided in Section 15.6(b). 
  
 (b) Upon any termination under this Agreement by TOPOTARGET pursuant to Section 15.3 other than as a result of any payment breach or any breach of Section 7.2(f), CURAGEN shall retain its rights to exploit the
licenses granted pursuant to Section 7.2 for the First Product and for all Future Products for which CURAGEN has paid any Take Up Fee as provided in Section 9.4, and, subject to Section 7.2(e), for all corresponding Back-Up Products, in all cases
subject to continued compliance with the relevant terms of this Agreement. TOPOTARGET shall retain its rights as provided in Section 15.6(b). 
  
 (c) Upon any termination of this Agreement by TOPOTARGET pursuant to Section 15.3 as a result of a payment breach, CURAGEN shall no longer
have rights to any Collaboration Products in any countries in the Territory and any and all licenses granted to CURAGEN hereunder, and all sublicenses, shall terminate. TOPOTARGET shall thereafter have rights as provided in Section 15.6(a) with
respect to all Collaboration Products in all countries, and shall retain its rights as provided in Section 15.6(b). 
  
 (d) Upon any termination under this Agreement by TOPOTARGET pursuant to Section 15.3 as a result of a breach of Section 7.2(f) and not
also as a result of a payment breach, CURAGEN shall no longer have rights in the Territory with respect to the relevant Collaboration Products for which breach of Section 7.2(f) was grounds for termination and any and all relevant licenses granted
to CURAGEN, and all relevant sublicenses, shall terminate for the relevant Collaboration Product. However, CURAGEN shall retain its rights to exploit the licenses granted pursuant to Section 7.2 for all other Collaboration Products. TOPOTARGET shall
thereafter have rights as provided in Section 15.6(a) for those Collaboration Products which were the subject of the breach of Section 7.2(f), and shall retain its rights as provided in Section 15.6(b). 
  
 (e) Upon termination under this Agreement by CURAGEN
pursuant to 15.3, CURAGEN shall retain its rights to exploit the licenses granted pursuant to Section 7.2 for the 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	74









 
First Product and for all Future Products identified prior to such termination and, subject to Section 7.2(e), for all corresponding Back-Up Products,
subject to continued compliance with the relevant terms of this Agreement, including without limitation payment obligations, other than those requiring collaboration with TOPOTARGET. In addition, the rights granted to CURAGEN pursuant to Section 3.5
shall survive such termination and CURAGEN shall receive additional rights as provided in Section 15.6(c). Notwithstanding the foregoing, in the event that any such termination by CURAGEN is the result of a payment breach by TOPOTARGET, the
Territory as defined herein shall become worldwide and CURAGEN’s continuing rights pursuant to Section 7.2 shall be exclusive in such expanded Territory and TOPOTARGET’s rights pursuant to Sections 7.4, 7.5 and 8.5 shall terminate with
respect to all Collaboration Products. 
  
 15.6 Access to
Rights Following Termination. 
  
 (a) For all
Collaboration Products for which CURAGEN’s rights do not continue following termination as provided in Sections 15.5(a), (b), (c), or (d) above, subject to (x) and (y) below, CURAGEN shall have no further rights pursuant to Section 7.2 for the
relevant Collaboration Products following such termination and CURAGEN shall: 
  
 (i) transfer and assign to TOPOTARGET all of CURAGEN’s right, title and interest in and to any CURAGEN Collaboration Technology and all data, reports, records, materials and other intellectual property owned or
controlled by CURAGEN that relates exclusively to such Collaboration Products; 
  
 (ii) grant TOPOTARGET a non-exclusive license, solely for the purpose of TOPOTARGET’s developing, making, having made, using,
marketing and selling such Collaboration Products, under any CURAGEN Licensed Technology and CURAGEN Collaboration Technology that does not exclusively relate to such Collaboration Products; 
  
 (iii) transfer and assign to TOPOTARGET ownership of all
INDs, NDAs and other regulatory filings made or filed with respect to any such Collaboration Product (or, if such transfer and assignment is not permitted under 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	75









 
the laws of any applicable jurisdiction, CURAGEN shall take such other permitted actions with respect to such filings as may be reasonably requested by
TOPOTARGET); 
  
 all upon commercially reasonable, arms length financial terms,
which shall in no event exceed royalties in amounts as specified in Section 9.9, that the Parties shall negotiate in good faith and agree upon as soon as practicable after such termination of this Agreement. In the event the Parties, despite the
mutual use of good faith efforts, are unable to agree upon such terms and conditions within six (6) months of the relevant termination date, the Parties shall appoint an independent valuation expert who shall determine such terms and conditions,
which determination shall be binding upon the Parties. If the Parties are unable to agree upon the appointment of such an expert, then each Party shall nominate an expert (the cost of whom shall be borne by such Party), and both experts appointed by
the Parties shall jointly appoint the expert who shall make such determination. Any expert appointed pursuant to this Section 15.6(a) shall have at least 15 years’ experience in the business of pharmaceutical development and commercialization.
Except as provided above, the costs and expenses of any expert acting under this Section 15.6(a) shall be borne equally by the Parties. Notwithstanding any other provision hereof, in the event that the royalty set pursuant to this Section 15.6(a) is
less than that specified in Section 9.9, such reduced royalty shall apply both inside and outside the TOPOTARGET Territory for the relevant Collaboration Product(s). 
  
 Notwithstanding the foregoing: (x) in the event of any termination of this Agreement in which CURAGEN loses rights for any
Collaboration Product with respect to fewer than all of the countries in the Territory, any rights, licenses and other benefits to be transferred, granted and otherwise assigned to TOPOTARGET as provided above for such Collaboration Product shall be
expressly limited to those pertaining to the countries in the Territory to which such termination applies; and (y) at any time prior to any transfer, granting and assignment of rights, licenses and benefits to TOPOTARGET pursuant to this Section
15.6(a), TOPOTARGET may elect, upon notice to CURAGEN, to waive the application of this Section 15.6(a) with respect to such rights, licenses and benefits. Following any such waiver neither Party shall have any obligation or liability to the other
with respect to such rights, licenses and benefits. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	76









 (b) In the event of any termination of this Agreement by TOPOTARGET pursuant to Section
15.3 or by CURAGEN pursuant to Section 15.4, TOPOTARGET’s license rights pursuant to Sections 7.4 and 7.5 hereof, and its rights pursuant to Section 8.5 hereof, shall continue subject to continued compliance with the relevant terms of this
Agreement; and provided that all royalties due to CURAGEN pursuant to Section 9.9 and/or Section 15.6(a) shall thereafter be payable to CURAGEN in accordance with Article 10 unless offsettable against milestones and royalties due with respect to any
surviving rights of CURAGEN. 
  
 (c) In the event
of termination of this Agreement by CURAGEN pursuant to Section 15.3, in addition to any relevant rights provided in Section 15.3(d), TOPOTARGET shall (i) promptly transfer to CURAGEN copies, whether in written or electronic form, of all data,
reports, records and materials (including any TOPOTARGET Licensed Technology and/or TOPOTARGET Collaboration Technology necessary to allow CURAGEN to continue to conduct the Research Program and the Development Program all to the extent not
previously disclosed to CURAGEN) in TOPOTARGET’s possession or control which relate to the Research Program and/or the Development Program; (ii) return to CURAGEN all relevant records and materials, whether in written or electronic form, in
TOPOTARGET’s possession or control containing Confidential Information of CURAGEN, and (iii) furnish to CURAGEN all unused Substances provided to TOPOTARGET by CURAGEN in connection with the Research Program. 
  
 15.7 Right to Sell Stock on Hand. CURAGEN shall have the right
for one year after any termination or expiration of this Agreement, to dispose of all Collaboration Product then in its inventory and to complete manufacture of and dispose of any work-in-progress then being manufactured, as though this Agreement
had not terminated. CURAGEN shall pay royalties thereon, in accordance with the provisions of this Agreement, as though this Agreement had not terminated. 
  
 15.8 Accrued Rights, Surviving Obligations. 
  
 (a) Termination, relinquishment or expiration of this Agreement for any reason shall be without prejudice to any rights which shall have
accrued to the benefit of either 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	77









 
Party prior to such termination, relinquishment or expiration. Such termination, relinquishment or expiration shall not relieve either Party from obligations
which are expressly indicated to survive termination or expiration of this Agreement. 
  
 (b) Termination, relinquishment or expiration of this Agreement shall not terminate each Party’s obligation to pay all royalties,
milestone payments and other monetary obligations that may have accrued hereunder prior to such termination. All of the Parties’ rights and obligations under Sections 4.7, 5.3(e), 5.5, 5.6, 5.7, 6.1, 6.2, 6.3, 6.4(d), 8.3, 8.5 (except in the
event of termination by CURAGEN for a payment breach by TOPOTARGET), 8.7, 8.8, 8.9, 9.9, 10, 12, 13 (solely with respect to actions pending at such time), 14, 15.2, 15.5, 15.6, 15.7, 15.8, 17.1 (if in effect at such time), 17.2 (if in effect at such
time), 17.4, 17.6, 17.12, 17.15, 17.16 and 17.17 shall survive termination, relinquishment or expiration hereof. 
  

	16.	FORCE MAJEURE. 

  
 16.1 Events of Force Majeure. Neither Party shall be held liable or responsible to the other Party nor be deemed to be in default under or
in breach of any provision of this Agreement for failure or delay in fulfilling or performing any obligation under this Agreement when such failure or delay is due to force majeure, and without the fault or negligence of the Party so failing or
delaying. For purposes of this Agreement, force majeure shall be defined as causes beyond the control of the Party, including, without limitation, acts of God; acts, regulations, or laws of any government; war; civil commotion; destruction of
production facilities or materials by fire, flood, earthquake, explosion or storm; labor disturbances; epidemic; and failure of public utilities or common carriers. In such event TOPOTARGET or CURAGEN, as the case may be, shall immediately notify
the other Party of such inability and of the period for which such inability is expected to continue. The Party giving such notice shall thereupon be excused from such of its obligations under this Agreement as it is thereby disabled from performing
for so long as it is so disabled and for 30 days thereafter. To the extent possible, each Party shall use reasonable efforts to minimize the duration of any force majeure. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	78










	17.	MISCELLANEOUS. 

  
 17.1 Non-Solicitation. During the term of the Research Program and for a period of one year thereafter, neither Party shall solicit, induce,
encourage or attempt to induce or encourage any employee of the other Party to terminate his or her employment with such other Party or to breach any other obligation to such other Party. 
  
 17.2 Relationship of Parties. Nothing in this Agreement is intended or shall be deemed to constitute a
partnership, agency, employment or joint venture relationship between the Parties. Neither Party shall be entitled to, or shall, incur any debts or make any commitments for the other, except to the extent, if at all, specifically provided herein.

  
 17.3 Guaranty. TOPOTARGET A/S hereby
unconditionally guaranties the performance of all obligations of any TOPOTARGET Affiliate under this Agreement and the Supply Agreement, when executed. In the event of a breach by any TOPOTARGET Affiliate in the observance of the terms of this
Agreement, CURAGEN shall be entitled to proceed against either such TOPOTARGET Affiliate or directly against TOPOTARGET A/S, as CURAGEN may determine in its sole discretion, to enforce this Agreement. CURAGEN CORPORATION hereby unconditionally
guaranties the performance of all obligations of any CURAGEN Affiliate under this Agreement and the Supply Agreement, when executed. In the event of a breach by any CURAGEN Affiliate in the observance of the terms of this Agreement, TOPOTARGET shall
be entitled to proceed against either such CURAGEN Affiliate or directly against CURAGEN CORPORATION, as TOPOTARGET may determine in its sole discretion, to enforce this Agreement. 
  
 17.4 Assignment. 
  
 (a) Each Party shall be entitled to assign this Agreement to any of its Affiliates upon 60 days’ prior written notice to the other
Party; provided, however, that in the event of any such assignment, the assigning Party shall remain jointly and severally liable with respect to all of its obligations hereunder, and in the event of any default relating to any such
obligations, the other Party shall be entitled to proceed against either such Affiliate or directly against the assigning Party, as such other Party may determine in its sole discretion, to enforce this Agreement. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	79









 (b) Except as provided in Section 17.4(a), neither Party shall be entitled to assign its
rights hereunder without the express written consent of the other Party, except that each Party may assign this Agreement to any assignee of all or substantially all of such Party’s business (or that portion thereof to which this Agreement
relates) or in the event of such Party’s merger, consolidation or similar transaction. 
  
 (c) No assignment contemplated by this Section 17.4 shall be valid or effective unless and until the assignee/transferee shall agree in
writing to be bound by the provisions of this Agreement. 
  
 17.5 Disclaimer of Warranties. EXCEPT AS EXPRESSLY PROVIDED IN ARTICLE 2 AND SECTION 3.1, THE PARTIES EXPRESSLY DISCLAIM ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF THIRD PARTY RIGHTS, OR ARISING FROM A COURSE OF DEALING OR USAGE OF TRADE PRACTICE. 
  
 17.6 Further Actions. Each Party shall execute, acknowledge and deliver such further instruments, and take all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
  
 17.7 Notice. Any notice or request required or permitted to be given under or in connection with this Agreement shall be deemed to have been sufficiently given if in writing and personally delivered or
sent by certified mail (return receipt requested), facsimile transmission (receipt verified), or overnight express courier service (signature required), prepaid, to the Party for which such notice is intended, at the address set forth for such Party
below: 
  

	 	(i)	In the case of CURAGEN, to: 


	 	 	555 Long Wharf Drive 


	 	 	New Haven, CT 06511 


	 	 	Attention: President 


	 	 	Facsimile No.: 203-401-3333 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	80










	 	(ii)	In the case of TOPOTARGET, to: 


	 	 	Attention: 


	 	 	Facsimile No.: 

  
 or to such other address for such Party as it shall have specified by like notice to the other Party, provided that notices of a change of address shall be effective only upon actual receipt thereof. If delivered
personally or by facsimile transmission, the date of delivery shall be deemed to be the date on which such notice or request was given. If sent by overnight express courier service, the date of delivery shall be deemed to be the next business day
after such notice or request was deposited with such service. If sent by certified mail, the date of delivery shall be deemed to be the fifth business day after such notice or request was deposited with the postal service in the country of mailing.

  
 17.8 Use of Name. Except as otherwise provided
herein, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name or trademark of the other Party (including, without limitation, any Trademark) for any
purpose in connection with the performance of this Agreement. 
  
 17.9 Public Announcements. 
  
 (a) Except as required by law (including, without limitation, the applicable disclosure requirements of any relevant regulatory authority or stock exchange) and as permitted by Section 12.2, neither Party shall make any public announcement
concerning this Agreement, any Covered Product or any other subject matter hereof without the prior written consent of the other Party, which shall not be unreasonably withheld or delayed. It shall not be unreasonable for a Party to withhold consent
with respect to any public announcement containing any of such Party’s Confidential Information. In the event of any required or proposed public announcement, (i) the Parties shall consult with each other in good faith as to the timing thereof,
and (ii) the Party making such announcement shall provide the other Party with a copy of the proposed text prior to such announcement sufficiently in advance of the scheduled release of such announcement to afford such other Party a reasonable
opportunity to review and comment upon the proposed text. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	81









 (b) Following a Party’s consent to or approval of the public announcement of any
information pursuant to this Section 17.9, both Parties shall be entitled to make subsequent public announcements of such information without renewed compliance with this Section 17.9, unless the scope and/or duration of such consent or approval is
expressly limited. 
  
 (c) Notwithstanding the
foregoing, on the Effective Date the Parties shall issue one or more press releases in the form attached hereto as Exhibit J, the timing of which shall be mutually agreed. 
  
 17.10 Waiver. A waiver by either Party of any of the terms and conditions of this Agreement in any instance
shall not be deemed or construed to be a waiver of such term or condition for the future, or of any subsequent breach hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative, and none of
them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party. 
  
 17.11 Compliance with Law. Nothing in this Agreement shall be deemed to permit a Party to export, re-export or otherwise transfer any
Collaboration Product sold under this Agreement without compliance with applicable laws. 
  
 17.12 Severability. When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to
be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. 
  
 17.13 Amendment. No amendment, modification or supplement of
any provisions of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	82









 17.14 Governing Law; English Original; Jurisdiction. 
  
 (a) This Agreement shall be governed by and interpreted in
accordance with the laws of the State of New York without regard to its choice of law principles; provided, however, that any arbitration proceeding conducted pursuant to Section 17.15 shall be governed by the Convention on the Recognition
and Enforcement of Foreign Arbitral Awards of June 10, 1958. The English original of this Agreement shall prevail over any translation hereof. 
  
 (b) Without prejudice to the rights and obligations of the Parties under Section 17.15, each Party hereby consents to the in personam
jurisdiction of any state or federal court sitting in the State of New York with respect to any matter arising in connection with this Agreement and further consents to the service of any process, notice of motion or other application to any such
court or a judge thereof outside the State of New York by registered or certified mail or personal service, provided that reasonable time is allowed for appearance. Each Party hereby waives, to the greatest extent it may do so, any defense it may
have on the grounds of inconvenient forum with respect to any action or proceeding maintained in any state or federal court in New York. 
  
 17.15 Arbitration. 
  
 (a) Any dispute arising out of or relating to any provisions of this Agreement (a “Dispute”) shall first be referred to the
professional mediator for resolution through good faith mediation (“Mediation”) involving the Chief Executive Officers of each respective Party. If the Dispute is not resolved by such individuals within thirty (30) days of written request
of either Party for Mediation, then the Dispute shall be resolved as provided in (b) below. 
  
 (b) Any Dispute which is not resolved by Mediation as provided in (a) above shall be finally settled by arbitration to be held in New
York, New York, under the auspices and then current commercial arbitration rules of the American Arbitration Association (the “AAA”). Such arbitration shall be conducted by three arbitrators. Within 30 days after the commencement of any
arbitration, each Party shall appoint one arbitrator, and these two arbitrators shall jointly appoint the third arbitrator, who shall have significant experience in pharmaceutical drug development and commercialization; provided, however,
that if the two arbitrators appointed by the Parties are unable to agree upon the third arbitrator within 30 days after their appointment, 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	83









 
then the third arbitrator shall be appointed by the AAA. The Parties shall instruct such arbitrators to render a determination of any such dispute within
four months after their appointment. All arbitration proceedings shall be conducted in English. Judgment upon any award rendered may be entered in any court having jurisdiction, or application may be made to such court for a judicial acceptance of
the award and an order of enforcement, as the case may be. 
  
 (c) Neither Section 17.15(a) or (b) shall prohibit a Party from seeking injunctive relief from a court of competent jurisdiction in the event of a breach or prospective breach of Section 3.4 or Articles 6, 7 or 12 of
this Agreement by the other Party which would cause irreparable harm to the first Party. 
  
 17.16 No Consequential Damages. IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS RESPECTIVE AFFILIATES OR SUBLICENSEES BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES OR SUBLICENSEES FOR SPECIAL,
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFITS OR REVENUE, OR CLAIMS OF CUSTOMERS OF ANY OF THEM OR OTHER THIRD PARTIES
FOR SUCH OR OTHER DAMAGES. 
  
 17.17 Entire
Agreement. This Agreement (together with the Exhibits hereto and the Research Plans, as approved and modified from time to time by the Joint Steering Committee) sets forth the entire agreement and understanding between the Parties as to the
subject matter hereof and merges all prior discussions and negotiations between them, and neither of the Parties shall be bound by any conditions, definitions, warranties, understandings or representations with respect to such subject matter other
than as expressly provided herein or as duly set forth on or subsequent to the Effective Date in writing and signed by a proper and duly authorized officer or representative of the Party to be bound thereby. Without limiting the generality of the
foregoing, the terms and conditions of this Agreement shall supersede the terms and conditions of any 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	84









 
confidentiality, non-disclosure or similar such agreement that the Parties may have executed prior to the Effective Date. 
  
 17.18 Parties in Interest. All the terms and provisions of this
Agreement shall be binding upon, inure to the benefit of and be enforceable by the Parties hereto and their respective permitted successors and assigns. 
  
 17.19 Section 365(n). All licenses granted under this Agreement are deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy
Code, licenses of rights to “intellectual property” as defined in Section 101 of such Code. The Parties agree that either Party may fully exercise all of its rights and elections under the U.S. Bankruptcy Code, regardless of whether the
other Party files for bankruptcy in the United States or another jurisdiction. The Parties further agree that, in the event the non-insolvent Party elects to retain its rights as a licensee under such Code, such Party shall be entitled to complete
access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology shall be delivered to such Party not later than; 
  
 (a) the commencement of bankruptcy proceedings against the insolvent Party, upon written request, unless
such insolvent Party elects to perform its obligations under the Agreement, or 
  
 (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the insolvent Party, upon written request.

  
 17.20 Descriptive Headings. The descriptive
headings of this Agreement are for convenience only, and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement. 
  

17.21 Counterparts. This Agreement may be executed simultaneously in two counterparts, any one of which need not contain the signature of
more than one Party, but both such counterparts taken together shall constitute one and the same agreement. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	85









 17.22 Construction. The Parties hereto acknowledge and agree that: (i) each Party and its
counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the
interpretation of this Agreement; and (iii) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in favor of or against any Party, regardless of which Party was generally responsible for the
preparation of this Agreement. 
  
 17.23
Hart-Scott-Rodino Filing. The Parties shall cooperate fully and use all commercially reasonable efforts to comply with the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations issued thereunder
(the “HSR Act”), to determine if a Notification Report is required thereunder, and to file any required Notification Report form with the Federal Trade Commission and the Department of Justice in accordance with such rules and regulations,
with respect to the transactions contemplated in this Agreement. 
  
 * * * 
  
 IN WITNESS WHEREOF, each of the Parties has
caused this Agreement to be executed by its duly authorized officer as of the day and year first above written. 
  

			
	TOPOTARGET A/S
		
	By:	 	 
		
	 Name:
	 	 
		
	 Title:
	 	 
	
	CURAGEN CORPORATION
		
	By:	 	 
		
	 Name:
	 	 
		
	 Title:
	 	 


  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	86









  
 EXHIBIT A 

 
 EXISTING TOPOTARGET LICENSED TECHNOLOGY 
  
 [***********] 
 [*************************************] 
 [*************************************] 
 [*************************************] 
 [*************************************] 
  
 [***********]: 
  
 [***************************************************] 
  
 [*************************************] 
  

									
	[************]	 	[*********]	 	[************]	 	[**********]	 	[************]
					
	[********]	 	[********]	 	[********]	 	[********]	 	[********]
					
	[********]	 	[********]	 	[********]	 	[********]	 	[********]
					
	[********]	 	[********]	 	[********]	 	[********]	 	[********]

  
 *[*************************************] 
  
 [******************************************************************************************************** 
 ********************************************************************************************************* 
 *************************************************] 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	1









 [**********]: 
  
 [************************************************************] 
 [*********************************] 
  

							
	[********]	 	[********]	 	[********]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 

  
 [************************************************************] 
 [*********************************] 
  

							
	[********]	 	[********]	 	[********]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 

  
 [************************************************************] 
 [*********************************] 
  

							
	[********]	 	[********]	 	[********]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 

  
 [************************************************************] 
 [*********************************] 
  

							
	[********]	 	[********]	 	[********]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	2









 [************************************************************] 
 [*********************************] 
  

							
	[********]	 	[********]	 	[********]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 

  
 [************************************************************] 
 [*********************************] 
  

							
	[********]	 	[********]	 	[********]	 	 
	[************]	 	[************]	 	[************]	 	 
	[************]	 	[************]	 	[************]	 	 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	3









  
 EXHIBIT B 

 
 JOINT STEERING COMMITTEE 
  
 Initial TOPOTARGET Representatives: 
  
 [***********************] 
  
 [*****************] 
  
 [*****************] 
  
 Initial CURAGEN Representatives: 
  
 [***********************] 
  
 [*****************] 
  
 [*****************] 
  
 Chairperson: 
  
 [***********************] 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	4









  
 EXHIBIT C 

 
 INITIAL RESEARCH PLAN 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	5









  
 EXHIBIT D 

 
 HDAC INHIBITOR CRITERIA 
  
 [*******************************************************] 
  
 [*******************************************************] 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	6









  
 EXHIBIT E 

 
 FORM OF MATERIAL TRANSFER AGREEMENT 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	7









  
 EXHIBIT F 

 
 DEVELOPMENT PROGRAM PRINCIPLES 
  
 TopoTarget and CuraGen have entered into a collaboration agreement to jointly develop HDAC
inhibitors in cancer, as well as potentially other indications. The collaboration will be governed by a global joint steering committee (JSC). This exhibit lays out the principles by which the JSC will manage the clinical development of
Collaboration Products. 
  
 Collaboration Goal 
  
 The goal of the collaboration is submission and registration in major markets of a medically
important, competitive Collaboration Product in industry competitive timelines. The initial focus will be in oncology. 
  
 The JSC will manage all aspects of development in a manner consistent with this goal. This includes work performed by CuraGen, TopoTarget, or other collaborators (e.g.
NCI), as well as all CMC work. 
  
 JSC Governance of Development Program

  
 To meet its mandate, it is assumed that the JMC will meet in person once
per quarter, and by remote means at all other monthly intervals. 
  
 The JSC
reviews, approves, measures and manages the global development plan on an ongoing basis. A joint team of TopoTarget and CuraGen employees with appropriate development expertise will develop and implement the plan with appropriate measures by which
to measure progress against plan as well as develop contingencies to manage variance to plan. As milestones are reached, this team will analyze data and communicate the implications of the data to the JSC. After initial generation and agreement to a
clinical development plan for each Collaboration Product, plans should be reviewed for modification at least once a year, or more frequently if needed, based on emerging clinical data or other environmental changes. In events where it is needed,
CuraGen will have the ability to break deadlocks within the JSC. 
  
 Principles
for JSC Management of the Development Program 
  
 TopoTarget and CuraGen will
jointly develop a global development plan for each Collaboration Product and determine who will be responsible for execution of various parts of the plan. In general, TopoTarget will be responsible for executing development activities in Europe and
CuraGen will be responsible for executing development activities elsewhere. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	8









 Principles of ICH should be followed including the principle of common technical documentation (CTD). This enables the
same material body of information, analyses, and conclusions, as ultimately embodied in the product label, to serve the purposes of registration globally, including specifically the EU and NA. 
  
 Both parties will agree on and have the option to participate in venues where external input
is sought for development plans (external clinical and/or regulatory consultation). Where feasible, efforts should be made to represent both parties in material external events. 
  
 TopoTarget will manage all EU regulatory strategic and operational maters and CuraGen will manage all other regulatory strategic and
operational matters – both in a manner consistent with the global development plan. 
  
 To foster the goal of efficient clinical development, protocols, data management, and statistical analysis, medical report writing will be harmonized in a way that provides for efficient and consistent product
information. This information includes consistency with all ICH dictated terms (AEs, SAEs), inclusion/exclusion criteria, data collection (standard CRF pages wherever possible, a common data base, common edit checks for the data base), common
definitions for response rate, partial response, complete response and other efficacy parameters, common uses of oncology toxicity definitions based on accepted norms, common analytical methods and programming, internally consistent conclusions
across studies, common study monitoring methodology and study auditing. 
  
 Clear
mechanisms and responsibilities will be established to meet global requirements for expedited safety reporting, as well as for determining what consequences, if any, reported adverse events have on the risk-benefit of any ongoing clinical trials.

  
 Clear mechanisms and responsibilities will be established to provide a common
investigators’ brochure, and updates to it, as well as for IND annual reporting obligations. Whenever possible, these responsibilities will be synchronized as much as possible so that these documents are generated from the same database and
data cut-off time, thus supporting consistent analysis and conclusions. 
  
 TopoTarget and CuraGen will work jointly with NCI to facilitate NCI’s productive participation in the development program. With this in mind, TopoTarget and CuraGen will work to make sure that as to a much extent as is reasonable, NCI
fits the development governance paradigm described above. 
  
 Initial Clinical
Development Program for PXD101 
  
 Within [********], TopoTarget and CuraGen
will agree on a draft global development plan for PXD101. Within [********] thereafter, TopoTarget and CuraGen will meet with external 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	9









 
clinical advisors to review the draft plan, modify it based on their input, and agree to a final development plan. 
  
 The final plan will specify the party responsible for executing the planned clinical trials,
incorporating the specifics: 
  
 TopoTarget will complete an ongoing Phase 1 study
of PDX101 in solid tumors (TT20) and initiate and complete a Phase 1 study, followed by a Phase 2 study in [***************(************)]. 
  
 CuraGen will prepare an IND for US filing, with the objective of commencing Phase 2 trials in [********]. 
  
 In addition, TopoTarget has signed a LOI for a CRADA with the NCI. Discussions have begun with the NCI in terms of their potential role in
exploring alternative dosing schedules and combination therapy. CuraGen will become involved in the CRADA as a third party. As part of the global development plan as governed by the JSC, TopoTarget and CuraGen will determine the optimal utilization
of this CRADA from the TopoTarget/CuraGen perspective and jointly represent this to the NCI. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	10









  
 EXHIBIT G 

 
 TOPOTARGET CLINICAL STUDIES 
  
 [************************************************************************]. 
  
 [************************************************************************]. 
  
 [************************************************************************]. 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	11









  
 EXHIBIT H 

 
 CONVERTIBLE DEBENTURE 
  
 AND 
  
 CONVERTIBLE LOAN AGREEMENT 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	12









  
 EXHIBIT I 

 
 FAIR MARKET VALUE METHODOLOGY 
  

					
	[**************************]	  	[******************]	  	 
			
	[**************************]	  	[******************]	  	 
			
	[**************************]	  	 [******************]
	  	 

  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	13









  
 EXHIBIT J 

 
 FORM OF PRESS RELEASE 
  


	
	Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under
Rule 24b-2 under the Securities Exchange Act of 1934.
	
	14